##### Table of Contents

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549



---

FORM 10-Q



---



|x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
|- | ----------------------------------------------------------------------------------------

For the quarterly period ended March 31, 2007



| ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
|- | -----------------------------------------------------------------------------------------

For the transition period from  to

Commission File Number 000-26749



---

NATIONAL MEDICAL HEALTH CARD
SYSTEMS, INC.

(Exact name of Registrant as specified in its charter)



---



|                                                               |  |                                     
|-------------------------------------------------------------- |  | ------------------------------------
|Delaware                                                       |  | 11-2581812                          
|(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employee Identification No.)

26 Harbor Park Drive,

Port Washington, NY

(Address of principal executive offices)

11050

(Zip Code)

Registrants telephone number, including area code: (516) 605-6625

(Former Name, Former Address and Former Fiscal year, if Changed Since Last Report): Not Applicable



---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days.    Yes  x    No ̈

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of
accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check One):     Large Accelerated Filer ̈Accelerated Filer  x    Non-Accelerated Filer ̈

Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act).    Yes ̈No  x

Indicate the number of shares outstanding of the registrants common stock, as of the latest
practicable date: The registrant had 5,474,465 shares of common stock outstanding as of May 7, 2007.



---



---

##### Table of Contents

Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC.

QUARTERLY REPORT ON FORM 10-Q

INDEX

PART I  FINANCIAL INFORMATION



|                            |  |                                                                                                             |  |   
|--------------------------- |  | ----------------------------------------------------------------------------------------------------------- |  | --
|                            |  | Forward Looking Statements                                                                                  |  | 3 
|                            |  |                                                                                                            
|Item 1.                     |  | Condensed Financial Statements                                                                              |  |   
|                            |  |                                                                                                            
|                            |  | Consolidated Balance Sheets  March 31, 2007 (Unaudited) and June 30, 2006                                  |  | 4 
|                            |  |                                                                                                            
|                            |  | Consolidated Statements of Income (Unaudited)  For the three and nine months ended March 31, 2007 and 2006 |  | 5 
|                            |  |                                                                                                            
|                            |  | Consolidated Statement of Stockholders Equity (Unaudited)  For the nine months ended March 31, 2007       |  | 6 
|                            |  |                                                                                                            
|                            |  | Consolidated Statements of Cash Flows (Unaudited)  For the nine months ended March 31, 2007 and 2006       |  | 7 
|                            |  |                                                                                                            
|                            |  | Condensed Notes to the Consolidated Financial Statements (Unaudited)                                        |  | 8 
|                            |  |                                                                                                            
|Item 2.                     |  | Managements Discussion and Analysis of Financial Condition and Results of Operations                       |  | 20
|                            |  |                                                                                                            
|Item 3.                     |  | Quantitative and Qualitative Disclosures About Market Risk                                                  |  | 31
|                            |  |                                                                                                            
|Item 4.                     |  | Controls and Procedures                                                                                     |  | 31
|                            | 
|PART II  OTHER INFORMATION |  |                                                                                                            
|                            |  |                                                                                                            
|Item 1.                     |  | Legal Proceedings                                                                                           |  | 33
|                            |  |                                                                                                            
|Item 1A.                    |  | Risk Factors                                                                                                |  | 33
|                            |  |                                                                                                            
|Item 2.                     |  | Unregistered Sales of Equity Securities and Use of Proceeds                                                 |  | 35
|                            |  |                                                                                                            
|Item 3.                     |  | Defaults Upon Senior Securities                                                                             |  | 35
|                            |  |                                                                                                            
|Item 4.                     |  | Submission of Matters to a Vote of Security Holders                                                         |  | 35
|                            |  |                                                                                                            
|Item 5.                     |  | Other Information                                                                                           |  | 36
|                            |  |                                                                                                            
|Item 6.                     |  | Exhibits                                                                                                    |  | 36
|                            | 
|SIGNATURES                  |  | 38                                                                                                         



2



---

##### Table of Contents

Forward Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and
actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. The forward-looking statements are not
historical facts, but rather are based on current expectations, estimates, assumptions and projections about the business and future financial results of the PBM and specialty pharmacy industries and other legal, regulatory and economic
developments. We use words such as may, could, estimate, believe, anticipate, think, intend, expect and similar expressions to identify these
forward-looking statements. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors. These factors include risks relating to pricing, competition in the bidding and
proposal process, our ability to consummate contract negotiations with prospective clients, dependence on key members of management, government regulation, acquisitions and affiliations, the market for pharmacy benefit management services and other
factors.

The foregoing factors are not exhaustive. You should carefully consider the foregoing factors and the other uncertainties and potential events
described in our Annual Report on Form 10-K and other documents filed from time to time with the Securities and Exchange Commission.



3



---

##### Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except for per share data)



|                                                                                                                                                                                  |  |                |         |   |               |   |         |  
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | -------------- | ------- | - | ------------- | - | ------- | -
|                                                                                                                                                                                  |  | March 31, 2007 |         |   | June 30, 2006 |  
|                                                                                                                                                                                  |  | (Unaudited)    |         |   |               |  
|Assets                                                                                                                                                                            |  |                |         |   |               |   |         |  
|Current Assets:                                                                                                                                                                   |  |                |         |   |               |   |         |  
|                                                                                                                                                                                  |  |               
|Cash and cash equivalents                                                                                                                                                         |  | $              | 5,620   |   |               | $ | 8,410   |  
|Restricted cash                                                                                                                                                                   |  |                | 9,481   |   |               |   | 4,845   |  
|Accounts receivable, net of allowance for doubtful accounts of $2,226 and $2,261 respectively                                                                                     |  |                | 67,941  |   |               |   | 82,365  |  
|Rebates receivable                                                                                                                                                                |  |                | 43,042  |   |               |   | 48,911  |  
|Inventory                                                                                                                                                                         |  |                | 4,453   |   |               |   | 5,666   |  
|Deferred tax assets                                                                                                                                                               |  |                | 1,797   |   |               |   | 2,278   |  
|Prepaid expenses and other current assets                                                                                                                                         |  |                | 3,876   |   |               |   | 2,623   |  
|                                                                                                                                                                                  |  |                |         |   |               |   |         |  
|Total current assets                                                                                                                                                              |  |                | 136,210 |   |               |   | 155,098 |  
|                                                                                                                                                                                  |  |               
|Property and equipment, net                                                                                                                                                       |  |                | 16,366  |   |               |   | 13,653  |  
|Intangible assets, net                                                                                                                                                            |  |                | 2,687   |   |               |   | 3,013   |  
|Goodwill                                                                                                                                                                          |  |                | 99,414  |   |               |   | 99,319  |  
|Other non-current assets                                                                                                                                                          |  |                | 1,418   |   |               |   | 1,070   |  
|                                                                                                                                                                                  |  |                |         |   |               |   |         |  
|Total Assets                                                                                                                                                                      |  | $              | 256,095 |   |               | $ | 272,153 |  
|                                                                                                                                                                                  |  |                |         |   |               |   |         |  
|Liabilities, Redeemable Preferred Equity and Common Stockholders Equity                                                                                                          |  |                |         |   |               |   |         |  
|Current Liabilities:                                                                                                                                                              |  |                |         |   |               |   |         |  
|                                                                                                                                                                                  |  |               
|Claims payable to pharmacies                                                                                                                                                      |  | $              | 62,300  |   |               | $ | 88,979  |  
|Rebates payable to clients                                                                                                                                                        |  |                | 55,173  |   |               |   | 60,953  |  
|Trade and other payables and accrued expenses                                                                                                                                     |  |                | 17,703  |   |               |   | 12,248  |  
|Current portion of capital lease obligations                                                                                                                                      |  |                | 1,124   |   |               |   | 16      |  
|Income taxes payable and other current liabilities                                                                                                                                |  |                | 2,819   |   |               |   |        |  
|                                                                                                                                                                                  |  |                |         |   |               |   |         |  
|Total current liabilities                                                                                                                                                         |  |                | 139,119 |   |               |   | 162,196 |  
|                                                                                                                                                                                  |  |               
|Capital lease obligations, less current portion                                                                                                                                   |  |                | 1,720   |   |               |   |        |  
|Other non-current liabilities                                                                                                                                                     |  |                | 915     |   |               |   | 829     |  
|Deferred tax liability                                                                                                                                                            |  |                | 8,759   |   |               |   | 7,784   |  
|                                                                                                                                                                                  |  |                |         |   |               |   |         |  
|Total liabilities                                                                                                                                                                 |  |                | 150,513 |   |               |   | 170,809 |  
|                                                                                                                                                                                  |  |                |         |   |               |   |         |  
|Commitments and Contingencies                                                                                                                                                     |  |                |         |   |               |   |         |  
|Redeemable Preferred Equity:                                                                                                                                                      |  |                |         |   |               |   |         |  
|                                                                                                                                                                                  |  |               
|Series A redeemable convertible preferred stock $0.10 par value; 15,000,000 shares authorized, 6,956,522 issued and outstanding, aggregate
liquidation preference of $107,686,961 |  |                | 76,694  |   |               |   | 76,338  |  
|                                                                                                                                                                                  |  |               
|Common Stockholders Equity:                                                                                                                                                      |  |                |         |   |               |   |         |  
|                                                                                                                                                                                  |  |               
|Common Stock, $.001 par value, 35,000,000 shares authorized, 10,111,837 and 9,933,697 shares issued, 5,471,937 and 5,293,797 outstanding,
respectively                            |  |                | 10      |   |               |   | 10      |  
|                                                                                                                                                                                  |  |               
|Additional paid-in-capital                                                                                                                                                        |  |                | 131,717 |   |               |   | 126,630 |  
|Accumulated deficit                                                                                                                                                               |  |                | (50,960 | ) |               |   | (49,755 | )
|Treasury stock at cost, 4,639,900 shares                                                                                                                                          |  |                | (51,879 | ) |               |   | (51,879 | )
|                                                                                                                                                                                  |  |                |         |   |               |   |         |  
|Total common stockholders equity                                                                                                                                                 |  |                | 28,888  |   |               |   | 25,006  |  
|                                                                                                                                                                                  |  |                |         |   |               |   |         |  
|Total Liabilities, Redeemable Preferred Equity and Common Stockholders Equity                                                                                                    |  | $              | 256,095 |   |               | $ | 272,153 |  
|                                                                                                                                                                                  |  |                |         |   |               |   |         |  

The accompanying condensed notes are an integral part of these consolidated financial
statements.



4



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except for per share data)

(UNAUDITED)



|                                                                                                                               |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|------------------------------------------------------------------------------------------------------------------------------ |  | ---------------------------- | ------- | - | --------------------------- | - | ------- | ---- |  | - | ------- | - |  | - | ------- | -
|                                                                                                                               |  | Three months ended March 31, |         |   | Nine months ended March 31, |  
|                                                                                                                               |  | 2007                         |         |   | 2006                        |   |         | 2007 |  |   | 2006    |  
|Revenue (excludes participant co-payments retained by the pharmacies of $53,393, $82,544, $198,683 and $243,043, respectively) |  | $                            | 145,026 |   |                             | $ | 216,801 |      |  | $ | 533,043 |   |  | $ | 651,402 |  
|Cost of claims (excludes co-payments retained by the pharmacies of $53,393, $82,544, $198,683 and $243,043, respectively)      |  |                              | 123,700 |   |                             |   | 194,381 |      |  |   | 466,819 |   |  |   | 581,742 |  
|                                                                                                                               |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|Gross profit                                                                                                                   |  |                              | 21,326  |   |                             |   | 22,420  |      |  |   | 66,224  |   |  |   | 69,660  |  
|                                                                                                                               |  |                              |         |  
|Selling, general and administrative expenses                                                                                   |  |                              | 21,402  |   |                             |   | 19,308  |      |  |   | 61,446  |   |  |   | 56,897  |  
|                                                                                                                               |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|Operating (loss) income                                                                                                        |  |                              | (76     | ) |                             |   | 3,112   |      |  |   | 4,778   |   |  |   | 12,763  |  
|                                                                                                                               |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|Other income (expense):                                                                                                        |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|Interest expense                                                                                                               |  |                              | (100    | ) |                             |   | (64     | )    |  |   | (350    | ) |  |   | (246    | )
|Interest income                                                                                                                |  |                              | 433     |   |                             |   | 433     |      |  |   | 1,245   |   |  |   | 1,053   |  
|Other income (expense), net                                                                                                    |  |                              | 1       |   |                             |   | 20      |      |  |   | 21      |   |  |   | (20     | )
|                                                                                                                               |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|                                                                                                                               |  |                              | 334     |   |                             |   | 389     |      |  |   | 916     |   |  |   | 787     |  
|                                                                                                                               |  |                              |         |  
|Income before (benefit) provision for income taxes                                                                             |  |                              | 258     |   |                             |   | 3,501   |      |  |   | 5,694   |   |  |   | 13,550  |  
|(Benefit) provision for income taxes                                                                                           |  |                              | (172    | ) |                             |   | 1,493   |      |  |   | 2,339   |   |  |   | 5,777   |  
|                                                                                                                               |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|Net income                                                                                                                     |  | $                            | 430     |   |                             | $ | 2,008   |      |  | $ | 3,355   |   |  | $ | 7,773   |  
|                                                                                                                               |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|Redeemable convertible preferred stock cash dividends                                                                          |  |                              | 1,381   |   |                             |   | 1,381   |      |  |   | 4,204   |   |  |   | 4,204   |  
|Accretion of transaction expenses                                                                                              |  |                              | 117     |   |                             |   | 117     |      |  |   | 356     |   |  |   | 356     |  
|                                                                                                                               |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|Net (loss) income available to common stockholders                                                                             |  | $                            | (1,068  | ) |                             | $ | 510     |      |  | $ | (1,205  | ) |  | $ | 3,213   |  
|                                                                                                                               |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|Earnings (loss) per common share:                                                                                              |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|Basic                                                                                                                          |  | $                            | (0.20   | ) |                             | $ | 0.10    |      |  | $ | (0.22   | ) |  | $ | 0.63    |  
|                                                                                                                               |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|Diluted *                                                                                                                      |  | $                            | (0.20   | ) |                             | $ | 0.10    |      |  | $ | (0.22   | ) |  | $ | 0.61    |  
|                                                                                                                               |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|Weighted average number of common shares outstanding:                                                                          |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|Basic                                                                                                                          |  |                              | 5,471   |   |                             |   | 5,200   |      |  |   | 5,443   |   |  |   | 5,111   |  
|                                                                                                                               |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  
|Diluted *                                                                                                                      |  |                              | 5,471   |   |                             |   | 5,302   |      |  |   | 5,443   |   |  |   | 5,268   |  
|                                                                                                                               |  |                              |         |   |                             |   |         |      |  |   |         |   |  |   |         |  

---

|* | For the three and nine months ended March 31, 2006, the redeemable convertible preferred stock was anti-dilutive and the as if converted method was not used to
calculate the number of weighted average diluted shares. For the three and nine months ended March 31, 2007, the redeemable convertible preferred stock and the outstanding options to purchase shares of common stock were anti-dilutive and the
as if converted method was not used to calculate the number of weighted average diluted shares.
|- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The
accompanying condensed notes are an integral part of these consolidated financial statements.



5



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF STOCKHOLDERS
EQUITY

(In thousands)

(UNAUDITED)



|                                                                      |  |              |  |                            |    |                     |   |         |                |        |         |       |  |       |  |   |         |   |  |   |        |  
|--------------------------------------------------------------------- |  | ------------ |  | -------------------------- | -- | ------------------- | - | ------- | -------------- | ------ | ------- | ----- |  | ----- |  | - | ------- | - |  | - | ------ | -
|                                                                      |  | Common Stock |  | Additional Paid-in Capital |    | Accumulated Deficit |   |         | Treasury Stock |        |         | Total | 
|                                                                      |  | Shares       |  | Amount                     |    |                     |   | Shares  |                | Amount |         |      
|Balances at June 30, 2006                                             |  | 9,934        |  | $                          | 10 |                     | $ | 126,630 |                | $      | (49,755 | )     |  | 4,640 |  | $ | (51,879 | ) |  | $ | 25,006 |  
|                                                                      |  |              |  |                            |    |                     |  
|Accretion of transaction expenses related to preferred stock offering |  |             |  |                            |   |                     |   |        |                |        | (356    | )     |  |      |  |   |        |   |  |   | (356   | )
|Exercise of stock options                                             |  | 178          |  |                            |   |                     |   | 1,858   |                |        |        |       |  |      |  |   |        |   |  |   | 1,858  |  
|Accrual of redeemable convertible preferred stock cash dividends      |  |             |  |                            |   |                     |   |        |                |        | (4,204  | )     |  |      |  |   |        |   |  |   | (4,204 | )
|Stock option income tax benefit                                       |  |             |  |                            |   |                     |   | 197     |                |        |        |       |  |      |  |   |        |   |  |   | 197    |  
|Stock-based compensation                                              |  |             |  |                            |   |                     |   | 3,032   |                |        |        |       |  |      |  |   |        |   |  |   | 3,032  |  
|Net income                                                            |  |             |  |                            |   |                     |   |        |                |        | 3,355   |       |  |      |  |   |        |   |  |   | 3,355  |  
|                                                                      |  |              |  |                            |    |                     |   |         |                |        |         |       |  |       |  |   |         |   |  |   |        |  
|Balances at March 31, 2007                                            |  | 10,112       |  | $                          | 10 |                     | $ | 131,717 |                | $      | (50,960 | )     |  | 4,640 |  | $ | (51,879 | ) |  | $ | 28,888 |  
|                                                                      |  |              |  |                            |    |                     |   |         |                |        |         |       |  |       |  |   |         |   |  |   |        |  

The accompanying condensed notes are an integral part of these consolidated financial
statements.



6



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(UNAUDITED)



|                                                                                  |  |                   |         |   |                |   |         |  
|--------------------------------------------------------------------------------- |  | ----------------- | ------- | - | -------------- | - | ------- | -
|                                                                                  |  | Nine Months Ended |        
|                                                                                  |  | March 31, 2007    |         |   | March 31, 2006 |  
|Cash flows from operating activities:                                             |  |                   |         |   |                |   |         |  
|Net income                                                                        |  | $                 | 3,355   |   |                | $ | 7,773   |  
|Adjustments to reconcile net income to net cash provided by operating activities: |  |                   |         |   |                |   |         |  
|Depreciation and amortization                                                     |  |                   | 7,108   |   |                |   | 5,399   |  
|Employee stock option compensation expense                                        |  |                   | 3,032   |   |                |   | 1,913   |  
|Amortization of deferred gain                                                     |  |                   | (21     | ) |                |   | (37     | )
|Amortization of deferred financing costs                                          |  |                   | 85      |   |                |   | 84      |  
|Loss on disposal of capital assets                                                |  |                   |        |   |                |   | 54      |  
|Provision for doubtful accounts                                                   |  |                   | 928     |   |                |   | 525     |  
|Deferred income taxes                                                             |  |                   | 1,456   |   |                |   | 1,276   |  
|Excess tax benefit from exercise of options                                       |  |                   |        |   |                |   | (1,237  | )
|Changes in assets and liabilities:                                                |  |                   |         |   |                |   |         |  
|Restricted cash                                                                   |  |                   | (4,636  | ) |                |   | (612    | )
|Accounts receivable                                                               |  |                   | 13,496  |   |                |   | 2,745   |  
|Rebates receivable                                                                |  |                   | 5,869   |   |                |   | (17,493 | )
|Inventory                                                                         |  |                   | 1,213   |   |                |   | (212    | )
|Due from affiliates                                                               |  |                   |        |   |                |   | 31      |  
|Prepaid expenses and other current assets                                         |  |                   | (1,253  | ) |                |   | 2,131   |  
|Other non-current assets                                                          |  |                   | (433    | ) |                |   | 9       |  
|Claims payable to pharmacies                                                      |  |                   | (26,679 | ) |                |   | (3,445  | )
|Rebates payable to clients                                                        |  |                   | (5,780  | ) |                |   | 13,216  |  
|Trade and other payables and accrued expenses                                     |  |                   | 4,791   |   |                |   | (6,869  | )
|Income taxes payable and other current liabilities                                |  |                   | 3,016   |   |                |   | 2,164   |  
|Other non-current liabilities                                                     |  |                   | 107     |   |                |   | (126    | )
|                                                                                  |  |                   |         |   |                |   |         |  
|Net cash provided by operating activities                                         |  |                   | 5,654   |   |                |   | 7,289   |  
|                                                                                  |  |                   |         |   |                |   |         |  
|Cash flows from investing activities:                                             |  |                   |         |   |                |   |         |  
|Capital expenditures                                                              |  |                   | (4,027  | ) |                |   | (5,869  | )
|Acquisition of PPP, net of cash acquired                                          |  |                   | (901    | ) |                |   | (426    | )
|Acquisition of Inteq, net of cash acquired                                        |  |                   |        |   |                |   | 116     |  
|Acquisition of MPP                                                                |  |                   | (266    | ) |                |   |        |  
|Proceeds from sale of capital assets                                              |  |                   | 5       |   |                |   | 169     |  
|                                                                                  |  |                   |         |   |                |   |         |  
|Net cash used in investing activities                                             |  |                   | (5,189  | ) |                |   | (6,010  | )
|                                                                                  |  |                   |         |   |                |   |         |  
|Cash flows from financing activities:                                             |  |                   |         |   |                |   |         |  
|Proceeds from exercise of stock options                                           |  |                   | 1,858   |   |                |   | 4,681   |  
|Proceeds from revolving credit facility                                           |  |                   | 26,850  |   |                |   | 72,075  |  
|Repayment of revolving credit facility                                            |  |                   | (26,850 | ) |                |   | (72,075 | )
|Payment of redeemable convertible preferred stock cash dividends                  |  |                   | (2,823  | ) |                |   | (4,204  | )
|Excess tax benefit from exercise of options                                       |  |                   |        |   |                |   | 1,237   |  
|Repayments of debt and capital lease obligations                                  |  |                   | (2,290  | ) |                |   | (21     | )
|                                                                                  |  |                   |         |   |                |   |         |  
|Net cash (used in) provided by financing activities                               |  |                   | (3,255  | ) |                |   | 1,693   |  
|                                                                                  |  |                   |         |   |                |   |         |  
|Net (decrease) increase in cash and cash equivalents                              |  |                   | (2,790  | ) |                |   | 2,972   |  
|Cash and cash equivalents at beginning of period                                  |  |                   | 8,410   |   |                |   | 7,272   |  
|                                                                                  |  |                   |         |   |                |   |         |  
|Cash and cash equivalents at end of period                                        |  | $                 | 5,620   |   |                | $ | 10,244  |  
|                                                                                  |  |                   |         |   |                |   |         |  

The accompanying condensed notes are an integral part of these consolidated financial
statements.



7



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(All in thousands, except share amounts)

(UNAUDITED)



1. BUSINESS AND BASIS OF PRESENTATION

National Medical Health Card Systems, Inc. (the Company or NMHC) provides comprehensive pharmacy benefit management (PBM) services to plan clients, which include managed care
organizations, local governments, unions, corporations and third party health care plan administrators through its network of licensed pharmacies throughout the United States. The Companys PBM services include electronic point-of-sale pharmacy
claims management, retail pharmacy network management, mail service pharmacy claims management, specialty pharmacy claims management, benefit design consultation, preferred drug management programs, drug review and analysis, consulting services,
disease information services, data access, reporting and information analysis, and physician profiling. In addition, the Company operates a mail service pharmacy and a specialty pharmacy.

The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany
accounts and transactions have been eliminated.

The accompanying unaudited interim condensed consolidated financial statements have been prepared pursuant
to the Securities and Exchange Commissions (SEC) rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States for
complete consolidated financial statements are not included herein. In the opinion of the Companys management, all adjustments, which include adjustments of a normal recurring nature necessary for a fair statement of the financial position,
results of operations and cash flows at the dates and for the periods presented, have been included. The results of operations for any interim period are not necessarily indicative of the results of operations for the full year. The unaudited
interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto as of June 30, 2006 included in the Companys Annual Report on Form 10-K.

Certain prior period amounts have been reclassified to conform to current period presentation.

2. RECENTLY ISSUED ACCOUNTING STANDARDS

In September 2006, the SEC issued Staff Accounting Bulletin
(SAB) No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (SAB No. 108) to provide guidance on the consideration of the
effects of prior year misstatements in quantifying current year misstatements for the purpose of a materiality assessment. Under SAB No. 108, companies should evaluate a misstatement based on its impact on the current year income statement, as
well as the cumulative effect of correcting such misstatements that existed in prior years existing in the current years ending balance sheet. SAB No. 108 will become effective for the Company in its fiscal year ending June 30, 2007.
The Company adopted the provisions of SAB No. 108 during the quarter ended September 30, 2006.

In July 2006, the Financial Accounting
Standards Board (FASB) issued Interpretation No. 48 (FIN 48), Accounting for Uncertainty in Income Taxes, which clarifies the accounting for uncertainty in income taxes recognized in the financial statements
in accordance with FASB Statement No. 109, Accounting for Income Taxes. FIN 48 provides guidance relative to the recognition, derecognition and measurement of tax positions for financial statement purposes. The standard also
required expanded disclosures. FIN 48 is effective for fiscal years beginning after December 15, 2006, with earlier adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.

3. MEDICARE PRESCRIPTION DRUG PLAN SPONSOR

In July
2006, NMHC Group Solutions Insurance, Inc. (NMHC Group Solutions), a Delaware corporation and subsidiary of the Company, received approval from the Centers for Medicare and Medicaid Services (CMS) to operate as a Medicare
Prescription Drug Plan (PDP) sponsor commencing January 1, 2007. On October 13, 2006, NMHC Group Solutions entered into a formal agreement with CMS to operate as a national PDP sponsor. As an approved PDP sponsor, NMHC
Group Solutions is able to operate as a risk-bearing entity for the individual enrollees and to employer groups. NMHC Group Solutions is currently acting as a risk-bearing entity for individual enrollees in its PDP. In order for NMHC Group Solutions
to maintain its licensures and continue to apply for licensure in the various states, it must fulfill statutory capital and surplus requirements. NMHC Group Solutions currently maintains $6,559 in a cash account to fulfill such requirements.
Currently, NMHC Group Solutions has obtained licensure in eight additional states to operate as a risk-bearing entity. As of March 31, 2007, NMHC Group Solutions had $100 in escrow for the protection of Delaware policyholders and an additional
$600 in Delaware accounts set aside to fulfill other state deposit requirements. CMS also requires that NMHC Group Solutions maintain $100 in a restricted escrow account for the benefit of policyholders to comply with insolvency
requirements.



8



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(All in thousands, except share amounts)

(UNAUDITED)



4. NEW MOUNTAIN TRANSACTION

The Company entered into an amended and restated preferred stock purchase agreement, dated as of November 26, 2003, with New Mountain Partners, L.P. (the purchase agreement). Pursuant to the purchase
agreement, the Company agreed, subject to various conditions, to issue to New Mountain Partners a total of 6,956,522 shares of series A redeemable convertible preferred stock (the series A preferred stock) at a purchase price of
$11.50 per share, for aggregate proceeds of approximately $80,000. On March 19, 2004, the Company completed the sale of the series A preferred stock to New Mountain Partners and used approximately $49,000 of the proceeds of the sale
of the series A preferred stock to purchase, pursuant to a tender offer, 4,448,900 shares of the Companys outstanding common stock at $11.00 per share (collectively, the New Mountain Transaction). Prior to the closing of the
New Mountain Transaction, Bert E. Brodsky, the former chairman of the board of directors, and certain stockholders related to him, held (assuming the exercise of 330,000 options and warrants held by Mr. Brodsky, which occurred in April 2004),
in the aggregate, approximately 59% of the Companys outstanding common stock and had agreed to tender 4,448,900 shares, or approximately 54% of the Companys outstanding common stock, held by them, into the tender offer. No other
stockholders tendered shares in the offer.

Following the completion of the tender offer, and assuming the exercise of 330,000 options and warrants held by
Mr. Brodsky, which occurred in April 2004, New Mountain Partners owned securities at March 19, 2004 that were initially convertible into approximately 64% of the Companys issued and outstanding common stock and prior to conversion of
the series A preferred stock were entitled to cast that number of votes that is equal to approximately 60% of the Companys aggregate voting power. Following the closing of the New Mountain Transaction, New Mountain Partners was entitled
to and did nominate and elect 60% of the members of the Companys board of directors.

The Company used the remaining proceeds from the issuance and
sale of the series A preferred stock of approximately $24,000, excluding expenses related to the closing of the New Mountain Transaction, for the Inteq acquisition described in Note 5  Business Acquisitions and for working
capital purposes.

The series A preferred stock provides for an initial annual cash dividend equal to 7% of the investment amount, which decreases to 3.5%
after the fifth anniversary of issuance. The series A preferred stock is convertible into common stock at a price of $11.50 per share of common stock, or an aggregate of 6,956,522 shares of the Companys common stock.

After March 19, 2008, if the Companys common stock is trading at or above a stated level, and subject to the satisfaction of other conditions, the Company
may, at its option, redeem shares of the series A preferred stock at a price equal to its reported value on the Companys consolidated balance sheet plus all unpaid dividends, whether or not declared. After March 19, 2011, the Company may,
at its option, redeem shares of series A preferred stock at a price equal to $11.50 per share plus all unpaid dividends, whether or not declared. After March 19, 2014, each holder of shares of series A preferred stock may require the
Company to redeem all or a part of that holders shares of series A preferred stock at price equal to $11.50 per share plus all unpaid dividends, whether or not declared.



9



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(All in thousands, except share amounts)

(UNAUDITED)



Subject to certain conditions, the liquidation value of the series A preferred stock is the greater of $11.50 per
share plus all unpaid dividends, whether or not declared, or the amount that would be payable to a holder of the series A preferred stock if the series A preferred stock was converted into common stock immediately prior to the liquidation.

Upon the closing of the New Mountain Transaction, the Company recorded a non-recurring, non-cash charge to net income available to holders of the
Companys common stock for a beneficial conversion feature related to the series A preferred stock, which is convertible into the Companys common stock at $11.50 per share. Such non-cash charge reflects the difference between the fair
market value of the Companys common stock on the date of the closing of the New Mountain Transaction ($24.00 per share as of March 19, 2004) and the effective conversion price of $11.29 (after deducting the closing payment of $1,450
payable to New Mountain Partners) multiplied by 6,956,552, the number of shares of the Companys common stock into which the series A preferred stock held by New Mountain Partners is convertible. The maximum amount of the beneficial conversion
feature was limited to $80,000, which is the purchase price of the series A preferred stock.

5. BUSINESS ACQUISITIONS

Maintenance Prescriptions Programs, Inc. In July 2006, the Company entered into an Asset Purchase Agreement with Maintenance Prescriptions Programs,
Inc., a New York corporation, and certain other owners named therein (collectively MPP), pursuant to which the Company agreed to acquire various customer contracts from MPP relating to their mail service business. The aggregate purchase
price of the acquired assets was $355. On July 31, 2006, the Company paid the former owners of MPP an initial deposit of $100 out of the Companys working capital with the remainder of the purchase price due by July 31, 2008. The
purchase price for these contracts was allocated to intangible assets and is being amortized over three (3) years. On January 12, 2007, the Company paid the former owners of MPP $166 towards the aggregate purchase price out of the
Companys working capital.

Pharmaceutical Care Network On March 7, 2005, the Company acquired all of the outstanding stock
of Pharmaceutical Care Network (PCN), a California corporation, from the California Pharmacists Association (CPhA). PCN provides customary PBM services to corporations, HMOs, insurance companies, third-party
administrators and union trusts. The aggregate purchase price of PCN was $13,000. In addition, the Company has agreed to pay earnouts to CPhA, as additional purchase price, up to $30,000 over a three-year period if certain financial and performance
targets are achieved. As of March 31, 2007, the financial and performance targets have not been achieved. The funds for the payment of the purchase price in connection with the PCN acquisition were obtained out of the Companys working
capital and JPMorgan credit facility. See Note 7, Line of Credit for more information. The PCN operations complement the Companys business while strengthening the Companys presence in the California marketplace as well as in
the managed Medicaid market.

In addition to the $13,000 purchase price for the acquisition of PCN, there were $561 of acquisition related expenses
incurred by the Company. Of the $13,000, $10,500 was paid to CPhA and certain of PCNs current and former employees who participated in its Long Term Incentive Plan, and $2,500 was deposited into escrow to secure CPhAs obligations under
the purchase agreement. Currently, all escrow to secure CPhAs obligations under the purchase agreement were released in accordance with the terms of the purchase agreement. At the time of the acquisition, PCN had approximately $30,942 of
assets which included $16,711 of cash, $2,734 of restricted cash, $3,204 of accounts receivable, $6,090 of rebates receivable, $1,139 of other assets and $1,064 of property and equipment. They also had approximately $27,040 of liabilities which
included $26,848 of claims and accounts payable, $97 of other current liabilities and $95 of other long-term liabilities. As a result of the PCN acquisition, $2,842 of severance and exit costs were accrued with $1,213 recorded as a deferred tax
asset and $1,629 recorded as additional goodwill. Of this amount, $1,349 was paid as of March 31, 2007 and $332 was offset against goodwill as various employees did not satisfy conditions to



10



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(All in thousands, except share amounts)

(UNAUDITED)



receive their originally designated severance package. The acquisition was accounted for under the purchase method of
accounting and the results of PCNs operations were included in the consolidated financial statements commencing as of the closing date of the PCN acquisition. The excess of the acquisition costs over the fair value of identifiable net assets
acquired was $12,053, which consists of the following components: know how and computer software valued at $870, which are being amortized over ten (10) years, customer relationships valued at $380, which are being amortized over
ten (10) years, and goodwill of $10,803. In accordance with Statement of Financial Accounting Standards (SFAS) No. 142, Goodwill and Other Intangible Assets, the goodwill is not being amortized.

Inteq On April 1, 2004, the Company entered into an Asset Purchase Agreement (the Agreement) with Inteq PBM, LP, a Texas limited
partnership, The INTEQ-RX Group, LLP and certain other owners named therein (together with The INTEQ-RX Group, LLP, Inteq), pursuant to which the Company agreed to acquire certain assets of Inteq relating to their PBM business. The Inteq
business complements the Companys business while strengthening the Companys presence in the Texas marketplace. The aggregate purchase price of Inteq was $31,500. In addition, the Company had agreed to pay earnouts to Inteq, as additional
purchase price, up to $4,200 over a one-year period if certain financial and performance targets were achieved during the one-year period following the closing. The Company required that $3,000 be deposited into escrow to cover the potential earnout
payments to Inteq. Of this amount, $1,024 of additional consideration was earned and released from escrow, with the balance of $1,976 being returned to the Company. Funds for the Inteq acquisition were obtained out of proceeds from the New Mountain
Transaction and the JPMorgan credit facility. See Note 4, New Mountain Transaction and Note 7, Line of Credit for more information. In connection with the Inteq acquisition, several members of Inteqs management remained
with the Company as consultants during the transition period.

The purchase price for the acquired assets of Inteq was $31,500 of which $29,640 was paid in
cash at closing and $1,860 was paid in the form of a promissory note. In addition, there was $702 of acquisition related expenses incurred by the Company. Of the $29,640, $24,900 was paid to Inteq, and $4,740 was deposited into escrow to secure
Inteqs indemnity obligations under the Agreement. The Company did not seek any indemnifications against Inteq and therefore released the $4,740 of escrow according to the terms of the Agreement.

At the time of the acquisition, Inteq had approximately $14,200 of assets, which included $4,134 of cash, $7,938 of accounts receivable, $2,041 of rebates receivable,
$47 of other assets and $40 of property and equipment. They also had approximately $11,151 of liabilities which included $11,138 of claims and accounts payable and $13 of miscellaneous payables. The acquisition was accounted for under the purchase
method of accounting and the results of Inteqs operations were included in the consolidated financial statements commencing with the acquisition date. The excess of the acquisition costs over the fair value of identifiable net assets acquired
was $29,153, which consists of the following components: customer relationships valued at $1,800, which are being amortized over ten (10) years and goodwill of $27,353. In accordance with SFAS No. 142, Goodwill and Other Intangible
Assets, the goodwill is not being amortized.

Ascend On July 31, 2003, the Company entered into a Stock Purchase Agreement
with Portland Professional Pharmacy (PPRX), Portland Professional Pharmacy Associates (PRXA, and together with PPRX, Specialty Specialty Pharmacy PPP or Ascend) and the
individual shareholders (the PPP Shareholders) to purchase all of the shares of PPP for $3,150. PPP provides specialty-pharmacy services in a broad range of areas, including womens health, pediatric care, mens health and
transplant. Funds for the PPP acquisition were supplied by the Companys revolving credit facility. See Note 7, Line of Credit for more information. The Company has positioned PPP as a preferred provider with PPPs target
markets while focusing on the extension of their specialty services to the Companys PBM division. In addition, the Company agreed to pay earnouts to the PPP Shareholders, as additional purchase price, up to $7,000 over a three-year period if
the PPP business achieved certain financial targets. At the Companys sole discretion, as much as 50% of the $7,000 could be paid in the form of the Companys common stock. For the first year



11



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(All in thousands, except share amounts)

(UNAUDITED)



ended July 31, 2004, $716 was earned and was settled on September 15, 2004. Of this amount, $358 was paid
in cash and $358 was paid in the form of the Companys common stock (12,650 shares at $28.30 per share). For the second year ended July 31, 2005, $850 was earned and was settled on September 15, 2005. Of this amount, $425 was paid in
cash and $425 was paid in the form of the Companys common stock (17,127 shares at $24.84 per share). For the third year through July 31, 2006, $931 was earned and settled on September 30, 2006. Of this amount, $901 was paid in cash
and $30 offset various legal fees paid by NMHC on behalf of the former PPP Shareholders. By a letter dated September 29, 2006, the former PPP Shareholders have requested a review of the earnout calculation.

The purchase price for the stock of PPP was $3,150. In addition, there was $77 of acquisition related expenses incurred by the Company. At the time of the acquisition,
PPP had approximately $1,664 of assets which included $177 of cash, $889 of accounts receivable, $539 of inventory and $59 of property and equipment. PPP also had approximately $1,423 of liabilities which included $609 of bank debt, which was paid
off at closing, and $814 of miscellaneous payables. The acquisition was accounted for under the purchase method of accounting and the results of PPPs operations were included in the consolidated financial statements commencing with the
acquisition date. The excess of the acquisition costs over the fair value of identifiable net assets acquired was $2,986, which consists of the following components: (i) customer relationships valued at $295, which are being amortized over
seven (7) years; (ii) employment and non-compete agreements valued at $100 each, which are being amortized over four (4) years; (iii) the Portland Professional Pharmacy trade name valued at $100 which is being amortized over four
(4) years; and (iv) goodwill of $2,391. From the date of acquisition through March 31, 2007, goodwill has increased by $2,497, which represents the cumulative amount of earnouts earned by PPP. In accordance with SFAS No. 142,
Goodwill and Other Intangible Assets, the goodwill is not being amortized. For tax purposes the Company has made an election which will allow it to amortize the goodwill and other intangibles over fifteen years.

6. GOODWILL AND INTANGIBLE ASSETS

The following is a summary of the
Companys goodwill and other intangible assets:



|                                          |  |        |        |              |   |       |  |   |       
|----------------------------------------- |  | ------ | ------ | ------------ | - | ----- |  | - | ------
|                                          |  | PBM(1) |        | Specialty(2) |   | Total
|Goodwill:                                 |  |        |        |              |   |       |  |   |       
|Balance as of June 30, 2006               |  | $      | 94,526 |              | $ | 4,793 |  | $ | 99,319
|Specialty additional consideration earned |  |        |       |              |   | 95    |  |   | 95    
|                                          |  |        |        |              |   |       |  |   |       
|Balance as of March 31, 2007              |  | $      | 94,526 |              | $ | 4,888 |  | $ | 99,414
|                                          |  |        |        |              |   |       |  |   |       



|                   |  |                     |       |                         |   |               |  |                     |       |                         |   |               |  |   |       |  |   |      
|------------------ |  | ------------------- | ----- | ----------------------- | - | ------------- |  | ------------------- | ----- | ----------------------- | - | ------------- |  | - | ----- |  | - | -----
|                   |  | March 31, 2007      |       | June 30, 2006          
|                   |  | GrossCarryingAmount |       | AccumulatedAmortization |   | Net BookValue |  | GrossCarryingAmount |       | AccumulatedAmortization |   | Net BookValue
|Intangible assets: |  |                     |       |                         |   |               |  |                     |       |                         |   |               |  |   |       |  |   |      
|PBM (1)            |  | $                   | 7,034 |                         | $ | 4,512         |  | $                   | 2,522 |                         | $ | 6,679         |  | $ | 3,919 |  | $ | 2,760
|Specialty (2)      |  |                     | 595   |                         |   | 430           |  |                     | 465   |                         |   | 595           |  |   | 342   |  |   | 253  
|                   |  |                     |       |                         |   |               |  |                     |       |                         |   |               |  |   |       |  |   |      
|Total              |  | $                   | 7,629 |                         | $ | 4,942         |  | $                   | 2,687 |                         | $ | 7,274         |  | $ | 4,261 |  | $ | 3,013
|                   |  |                     |       |                         |   |               |  |                     |       |                         |   |               |  |   |       |  |   |      

---

|(1) | Primarily comprised of the excess acquisition costs over the fair value of the net tangible and identifiable assets acquired by the Company, which has been allocated to goodwill and
intangible assets. The goodwill also includes any earnouts earned in conjunction with the acquisitions. The intangible assets consist primarily of customer relationships. See Note 5, Business Acquisitions for more information.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



12



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(All in thousands, except share amounts)

(UNAUDITED)



|(2) | Represents the Specialty Pharmacy segment primarily reflecting the excess of the Ascend purchase price over the net tangible and identifiable assets acquired, which has been
allocated to goodwill and intangible assets. The goodwill also includes any earnouts earned in conjunction with the acquisition. The change in goodwill from June 30, 2006 to March 31, 2007 is the result of final adjustments to earnouts in
connection with the Ascend acquisition. The intangible assets consist primarily of customer relationships and employment agreements. See Note 5, Business Acquisitions for more information.
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

As of March 31, 2007, approximately $82,021 of the Companys goodwill is deductible for income tax purposes on a straight-line basis over 15 years.

7. LINE OF CREDIT

On January 28, 2005, the Company and
certain of its subsidiaries entered into a five-year $65,000 line of credit with a syndicate of commercial banks led by JPMorgan Chase Bank, N.A. (JPMorgan). Subject to certain conditions including the consent of the existing lenders,
the line of credit (the JPMorgan credit facility) may be increased by an aggregate of $35,000.

Depending on the timing and dollar amount of
each loan request, the Company will either borrow at a spread above LIBOR, the overnight Federal Funds rate or JPMorgans prime rate. The initial spread was 1.75% for LIBOR and Federal Funds loans and 0.75% for prime rate loans. As of
March 31, 2007, the spread is 1.50% for LIBOR and Federal Funds loans and 0.50% for prime rate loans.

The JPMorgan credit facility is secured by the
Companys consolidated assets. The JPMorgan credit facility requires the Company to be in compliance with financial and other covenants. The three defined financial covenants include: consolidated net worth; consolidated fixed charge ratio; and
consolidated debt to EBITDA ratio. The Company was in compliance with all covenants at March 31, 2007 as set forth in the credit agreement in connection with the credit facility.

As of March 31, 2007, the Company had no outstanding borrowings under its line of credit.

The Company has a $250
irrevocable letter of credit which the Company has granted in favor of one of its clients to secure any indemnity obligations that may arise during the term of the client agreement. The irrevocable letter of credit is cancellable upon the
termination of the client agreement. As of March 31, 2007, no amounts were drawn down under this letter of credit.

8. SEGMENT REPORTING

As of March 31, 2007, the Company has two reportable segments, PBM and Specialty Pharmacy. The PBM segment includes the sale of traditional
prescription drugs to the Companys clients and their participants, either through the Companys nationwide network of pharmacies or the Companys mail service pharmacy. The Specialty Pharmacy segment primarily includes the sale of
higher margin specialty pharmacy products and services for the treatment of chronic and potentially life-threatening diseases.

The chief operating
decision maker assesses the Companys performance of its operating segments through their gross profit, defined as segment revenue less segment cost of claims. Selling, general and administrative expenses are reported as corporate
expenses. In addition, interest and other income and interest expense are reported in the corporate category.



13



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(All in thousands, except share amounts)

(UNAUDITED)



The following tables present selected financial information about the Companys reportable segments.



|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|-------------------------------------------- |  | --- | ------- | ------------------ | - | ------------------------ |  | - | --------- | - |  | ----- | ------ | - |  | - | ------- | -
|For the nine months ended March 31, 2007     |  | PBM |         | Specialty Pharmacy |   | Intersegment Elimination |  |   | Corporate |   |  | Total |       
|Revenue                                      |  | $   | 513,673 |                    | $ | 41,513                   |  | $ | (22,143   | ) |  | $     |       |   |  | $ | 533,043 |  
|Cost of claims                               |  |     | 449,849 |                    |   | 36,378                   |  |   | (19,408   | ) |  |       |       |   |  |   | 466,819 |  
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Gross profit                                 |  |     | 63,824  |                    |   | 5,135                    |  |   | (2,735    | ) |  |       |       |   |  |   | 66,224  |  
|Selling, general and administrative expenses |  |     |        |                    |   |                         |  |   |          |   |  |       | 61,446 |   |  |   | 61,446  |  
|Interest and other income                    |  |     |        |                    |   |                         |  |   |          |   |  |       | 1,266  |   |  |   | 1,266   |  
|Interest expense                             |  |     |        |                    |   |                         |  |   |          |   |  |       | (350   | ) |  |   | (350    | )
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Income before provision for income taxes     |  |     |        |                    |   |                         |  |   |          |   |  |       |       |   |  |   | 5,694   |  
|Provision for income taxes                   |  |     |        |                    |   |                         |  |   |          |   |  |       |       |   |  |   | 2,339   |  
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Net income                                   |  |     |        |                    |   |                         |  |   |          |   |  |       |       |   |  | $ | 3,355   |  
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Total identifiable assets                    |  | $   | 244,531 |                    | $ | 81,744                   |  | $ | (70,180   | ) |  |       |       |   |  | $ | 256,095 |  
|                                             |  |     |         |                    |  
|For the nine months ended March 31, 2006     |  | PBM |         | Specialty Pharmacy |   | Intersegment Elimination |  |   | Corporate |   |  | Total |       
|Revenue                                      |  | $   | 633,861 |                    | $ | 33,442                   |  | $ | (15,901   | ) |  | $     |       |   |  | $ | 651,402 |  
|Cost of claims                               |  |     | 566,507 |                    |   | 29,248                   |  |   | (14,013   | ) |  |       |       |   |  |   | 581,742 |  
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Gross profit                                 |  |     | 67,354  |                    |   | 4,194                    |  |   | (1,888    | ) |  |       |       |   |  |   | 69,660  |  
|Selling, general and administrative expenses |  |     |        |                    |   |                         |  |   |          |   |  |       | 56,897 |   |  |   | 56,897  |  
|Interest and other income                    |  |     |        |                    |   |                         |  |   |          |   |  |       | 1,033  |   |  |   | 1,033   |  
|Interest expense                             |  |     |        |                    |   |                         |  |   |          |   |  |       | (246   | ) |  |   | (246    | )
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Income before provision for income taxes     |  |     |        |                    |   |                         |  |   |          |   |  |       |       |   |  |   | 13,550  |  
|Provision for income taxes                   |  |     |        |                    |   |                         |  |   |          |   |  |       |       |   |  |   | 5,777   |  
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Net income                                   |  |     |        |                    |   |                         |  |   |          |   |  |       |       |   |  | $ | 7,773   |  
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Total identifiable assets                    |  | $   | 288,847 |                    | $ | 32,807                   |  | $ | (22,976   | ) |  |       |       |   |  | $ | 298,678 |  



|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|-------------------------------------------- |  | --- | ------- | ------------------ | - | ------------------------ |  | - | --------- | - |  | ----- | ------ | - |  | - | ------- | -
|For the three months ended March 31, 2007    |  | PBM |         | Specialty Pharmacy |   | Intersegment Elimination |  |   | Corporate |   |  | Total |       
|Revenue                                      |  | $   | 136,531 |                    | $ | 17,490                   |  | $ | (8,995    | ) |  | $     |       |   |  | $ | 145,026 |  
|Cost of claims                               |  |     | 116,234 |                    |   | 15,421                   |  |   | (7,955    | ) |  |       |       |   |  |   | 123,700 |  
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Gross profit                                 |  |     | 20,297  |                    |   | 2,069                    |  |   | (1,040    | ) |  |       |       |   |  |   | 21,326  |  
|Selling, general and administrative expenses |  |     |        |                    |   |                         |  |   |          |   |  |       | 21,402 |   |  |   | 21,402  |  
|Interest and other income                    |  |     |        |                    |   |                         |  |   |          |   |  |       | 434    |   |  |   | 434     |  
|Interest expense                             |  |     |        |                    |   |                         |  |   |          |   |  |       | (100   | ) |  |   | (100    | )
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Income before benefit from income taxes      |  |     |        |                    |   |                         |  |   |          |   |  |       |       |   |  |   | 258     |  
|Benefit from income taxes                    |  |     |        |                    |   |                         |  |   |          |   |  |       |       |   |  |   | (172    | )
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Net income                                   |  |     |        |                    |   |                         |  |   |          |   |  |       |       |   |  | $ | 430     |  
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Total identifiable assets                    |  | $   | 244,531 |                    | $ | 81,744                   |  | $ | (70,180   | ) |  |       |       |   |  | $ | 256,095 |  



|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|-------------------------------------------- |  | --- | ------- | ------------------ | - | ------------------------ |  | - | --------- | - |  | ----- | ------ | - |  | - | ------- | -
|For the three months ended March 31, 2006    |  | PBM |         | Specialty Pharmacy |   | Intersegment Elimination |  |   | Corporate |   |  | Total |       
|Revenue                                      |  | $   | 209,794 |                    | $ | 13,163                   |  | $ | (6,156    | ) |  | $     |       |   |  | $ | 216,801 |  
|Cost of claims                               |  |     | 188,231 |                    |   | 11,686                   |  |   | (5,536    | ) |  |       |       |   |  |   | 194,381 |  
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Gross profit                                 |  |     | 21,563  |                    |   | 1,477                    |  |   | (620      | ) |  |       |       |   |  |   | 22,420  |  
|Selling, general and administrative expenses |  |     |        |                    |   |                         |  |   |          |   |  |       | 19,308 |   |  |   | 19,308  |  
|Interest and other income                    |  |     |        |                    |   |                         |  |   |          |   |  |       | 453    |   |  |   | 453     |  
|Interest expense                             |  |     |        |                    |   |                         |  |   |          |   |  |       | (64    | ) |  |   | (64     | )
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Income before provision for income taxes     |  |     |        |                    |   |                         |  |   |          |   |  |       |       |   |  |   | 3,501   |  
|Provision for income taxes                   |  |     |        |                    |   |                         |  |   |          |   |  |       |       |   |  |   | 1,493   |  
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Net income                                   |  |     |        |                    |   |                         |  |   |          |   |  |       |       |   |  | $ | 2,008   |  
|                                             |  |     |         |                    |   |                          |  |   |           |   |  |       |        |   |  |   |         |  
|Total identifiable assets                    |  | $   | 288,847 |                    | $ | 32,807                   |  | $ | (22,976   | ) |  |       |       |   |  | $ | 298,678 |  



14



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(All in thousands, except share amounts)

(UNAUDITED)



9. EARNINGS PER SHARE

The following are reconciliations of the number of weighted average shares used in the basic and diluted earnings per share (EPS) calculation (in thousands):



|                                                     |  |                            |  |      
|---------------------------------------------------- |  | -------------------------- |  | -----
|                                                     |  | Quarters EndedMarch 31,   
|                                                     |  | 2007                       |  | 2006 
|Basic                                                |  | 5,471                      |  | 5,200
|Effect of assumed exercise of employee stock options |  |                           |  | 102  
|Series A preferred stock as if converted           |  |                           |  |     
|                                                     |  |                            |  |      
|Diluted                                              |  | 5,471                      |  | 5,302
|                                                     |  |                            |  |      
|                                                     | 
|                                                     |  | Nine Months EndedMarch 31,
|                                                     |  | 2007                       |  | 2006 
|Basic                                                |  | 5,443                      |  | 5,111
|Effect of assumed exercise of employee stock options |  |                           |  | 157  
|Series A preferred stock as if converted           |  |                           |  |     
|                                                     |  |                            |  |      
|Diluted                                              |  | 5,443                      |  | 5,268
|                                                     |  |                            |  |      

The Company reports EPS in accordance with SFAS No. 128, Earnings per Share. Basic EPS are
computed by dividing net income (loss) available to common stockholders by the weighted average number of shares of common stock issued and outstanding during the reporting period. Diluted EPS are calculated to give effect to all potentially
dilutive common shares that were outstanding during the reporting period. United States generally accepted accounting principles require all anti-dilutive securities, including convertible preferred stock, to be excluded from the diluted earnings
per share calculation. For the three and nine months ended March 31, 2006, all of the Companys redeemable convertible preferred stock issued to New Mountain Partners, L.P. was excluded from the diluted earnings per share calculation
because its inclusion would have been anti-dilutive. For the three and nine months ended March 31, 2007, all of the Companys redeemable convertible preferred stock issued to New Mountain Partners, L.P. and the outstanding options to
purchase shares of common stock were excluded from the diluted earnings per share calculation because their inclusion would have been anti-dilutive. If the Company were to include the assumed conversion of redeemable convertible preferred stock and
the outstanding options to purchase shares of common stock during the three and nine months ended March 31, 2007 and 2006, the Company would have added 6,956,522 equivalent shares of redeemable convertible preferred stock to the basic weighted
average shares outstanding to compute the diluted weighted average shares outstanding.



15



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(All in thousands, except share amounts)

(UNAUDITED)



|10. | EMPLOYEE BENEFIT PLANS
|--- | ----------------------

Restricted Stock Grant Plan

In October 2004, the Companys board of directors approved the adoption of the Companys Amended and Restated 2000 Restricted Stock Grant
Plan (the Stock Grant Plan), under which 700,000 shares of the Companys common stock have been reserved for issuance. The Stock Grant Plan provides for the issuance of shares of restricted stock or restricted stock units that are
subject to both standard restrictions on the sale or transfer of such shares and/or restrictions that the Companys board of directors may impose, such as restrictions relating to length of service, corporate performance or other restrictions.
All restricted stock and restricted stock unit awards are settled in shares of the Companys common stock.

All restricted stock awards issued under
the Stock Grant Plan are valued at the closing market value of the Companys common stock on the date of grant, and the total value of the award is expensed ratably over the service period of the employees receiving the grants. Share-based
compensation expense related to restricted stock awards outstanding during the three and nine months ended March 31, 2007 approximated $68 and $173, respectively. As of March 31, 2007, the total amount of unrecognized compensation cost
related to nonvested restricted stock awards was approximately $1,012, and the related weighted-average period over which it is expected to be recognized is approximately 39 months.

Nonvested restricted stock award activity for the nine months ended March 31, 2007 is as follows:



|                                                                |  |        |   |  |                                        |      
|--------------------------------------------------------------- |  | ------ | - |  | -------------------------------------- | -----
|                                                                |  | Shares |   |  | Weighted Average Grant Date Fair
Value
|Nonvested restricted stock awards outstanding at June 30, 2006  |  | 20,400 |   |  | $                                      | 26.99
|Restricted stock awards granted  unvested                      |  | 52,330 |   |  |                                        | 15.11
|Restricted stock awards  vested                                |  |       |   |  |                                        |     
|Restricted stock awards forfeited  unvested                    |  | (3,000 | ) |  |                                        | 24.61
|                                                                |  |        |   |  |                                        |      
|Nonvested restricted stock awards outstanding at March 31, 2007 |  | 69,730 |   |  | $                                      | 21.52
|                                                                |  |        |   |  |                                        |      

Employee Stock Option Plan

The Company grants stock options under the 1999 Stock Option Plan, as amended (the Plan). Stock option grants are designed to reward employees for their long-term contributions to the Company and provide
incentives for them to remain with the Company. The number and frequency of stock option grants are based on competitive practices, operating results of the Company, and government regulations.

The maximum number of shares of common stock issuable over the term of the Plan is limited to 4,850,000 shares plus an indeterminable number of shares of common stock
issuable upon the exercise of reload options. There are no options outstanding that contain the reload provision. The Plan permits the granting of stock options, stock grants, stock units and stock appreciation rights to
employees (including employee directors and officers) and consultants of the Company and its subsidiaries and affiliates, and non-employee directors of the Company. Options granted under the Plan have an exercise price of at least 100% of the fair
market value of the underlying stock, or 110% in the case of an individual who owns more than 10% of the combined voting power of all classes of stock of the Company on the grant date. Options granted under the Plan generally vest over a three or
four-year period. As of March 31, 2007, there are 729,408 options issuable under the Plan. Options granted during the nine months ended March 31, 2007 are exercisable at prices ranging from $13.04 to $15.55 and terminate seven to ten years
from the grant date. The total pretax intrinsic value of options exercised during the nine months ended March 31, 2007 was $900.

Summarized
information related to stock option activity is as follows:



|                                      |  |                   |   |  |                                           |      
|------------------------------------- |  | ----------------- | - |  | ----------------------------------------- | -----
|                                      |  | Number of Options |   |  | Weighted-Average Exercise Price Per
Share
|Outstanding options at June 30, 2006  |  | 1,510,556         |   |  | $                                         | 22.60
|Cancelled/Forfeited                   |  | (121,737          | ) |  |                                           | 23.99
|Granted                               |  | 365,540           |   |  |                                           | 14.19
|Exercised                             |  | (178,140          | ) |  |                                           | 10.43
|                                      |  |                   |   |  |                                           |      
|Outstanding options at March 31, 2007 |  | 1,576,219         |   |  | $                                         | 21.92
|                                      |  |                   |   |  |                                           |      



16



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(All in thousands, except share amounts)

(UNAUDITED)



The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2007:



|                         |  |                     |  |                                                        |  |                                           |       |                           |   |      
|------------------------ |  | ------------------- |  | ------------------------------------------------------ |  | ----------------------------------------- | ----- | ------------------------- | - | -----
|                         |  | Options Outstanding
|Range of Exercise Prices |  | Number Outstanding  |  | Weighted Average Remaining Contractual Life (in years) |  | Weighted Average Exercise Price Per share |       | Aggregate Intrinsic Value
|$ 7.19 to $10.78         |  | 88,599              |  | 0.63                                                   |  | $                                         | 8.25  |                           | $ | 641  
|$10.79 to $16.17         |  | 449,375             |  | 6.37                                                   |  |                                           | 13.92 |                           |   | 699  
|$16.18 to $24.26         |  | 266,089             |  | 6.84                                                   |  |                                           | 21.96 |                           |   |     
|$24.27 to $36.40         |  | 772,024             |  | 7.16                                                   |  |                                           | 28.13 |                           |   |     
|$36.41 to $36.66         |  | 132                 |  | 2.14                                                   |  |                                           | 36.66 |                           |   |     
|                         |  |                     |  |                                                        |  |                                           |       |                           |   |      
|                         |  | 1,576,219           |  | 6.51                                                   |  | $                                         | 21.92 |                           | $ | 1,340
|                         |  |                     |  |                                                        |  |                                           |       |                           |   |      
|                         | 
|                         |  | Options Exercisable
|Range of Exercise Prices |  | Number Exercisable  |  | Weighted Average Remaining Contractual Life (in years) |  | Weighted Average Exercise Price Per share |       | Aggregate Intrinsic Value
|$ 7.19 to $10.78         |  | 88,599              |  | 0.63                                                   |  | $                                         | 8.25  |                           | $ | 641  
|$10.79 to $16.17         |  | 76,235              |  | 1.50                                                   |  |                                           | 12.89 |                           |   | 197  
|$16.18 to $24.26         |  | 61,787              |  | 6.67                                                   |  |                                           | 21.49 |                           |   |     
|$24.27 to $36.40         |  | 286,091             |  | 6.02                                                   |  |                                           | 29.05 |                           |   |     
|$36.41 to $36.66         |  | 88                  |  | 2.14                                                   |  |                                           | 36.66 |                           |   |     
|                         |  |                     |  |                                                        |  |                                           |       |                           |   |      
|                         |  | 512,800             |  | 4.50                                                   |  | $                                         | 22.15 |                           | $ | 838  
|                         |  |                     |  |                                                        |  |                                           |       |                           |   |      

The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on options
with an exercise price less than the Companys closing stock price of $15.48 as of March 31, 2007, which would have been received by the option holders had those option holders exercised their options as of that date. The total number of
in-the-money options exercisable as of March 31, 2007 was 164,834.

Nonvested stock option activity for the nine months ended March 31, 2007 is
as follows:



|                                                |  |           |   |  |                                 |      
|----------------------------------------------- |  | --------- | - |  | ------------------------------- | -----
|                                                |  | Shares    |   |  | Weighted average Exercise price
|Nonvested options outstanding at June 30, 2006  |  | 1,036,724 |   |  | $                               | 25.36
|Options granted  unvested                      |  | 365,540   |   |  |                                 | 14.19
|Options vested                                  |  | (242,213  | ) |  |                                 | 24.33
|Options forfeited  unvested                    |  | (96,632   | ) |  |                                 | 24.71
|                                                |  |           |   |  |                                 |      
|Nonvested options outstanding at March 31, 2007 |  | 1,063,419 |   |  | $                               | 21.82
|                                                |  |           |   |  |                                 |      



17



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(All in thousands, except share amounts)

(UNAUDITED)



As of March 31, 2007, total compensation cost related to nonvested stock options not yet recognized was $8,392
which is expected to be recognized over the next 32 months on a weighted-average basis.

The Companys employee stock options have various
restrictions including vesting provisions and are often exercised prior to their contractual maturity. Lattice-binomial models are more capable of incorporating the features of the Companys employee stock options than closed-form models such
as the Black-Scholes model. The use of a lattice-binomial model requires the use of extensive actual employee exercise behavior data and the use of a number of complex assumptions including expected volatility, risk-free interest rate, expected
dividends, expected life of the options, post-vesting terminations and a sub-optimal exercise factor. The weighted-average grant date fair value of employee stock options granted during the nine months ended March 31, 2007 was $8.07 using the
lattice-binomial model with the following weighted-average assumptions:



|                            |  |           |  
|--------------------------- |  | --------- | -
|Expected volatility         |  | 58.2      | %
|Risk-free interest rate     |  | 4.73      | %
|Expected dividends          |  | 0.0       | %
|Expected life of the option |  | 5.5 years |  
|Post-vesting terminations   |  | 1.0       | %
|Sub-optimal exercise factor |  | 3.82      |  

Effective July 1, 2005, the Company adopted SFAS No. 123 (revised 2004), Share-Based
Payment, (SFAS No. 123(R)) which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors based on estimated fair values.

Stock-based compensation expense recognized under SFAS No. 123(R) for the three and nine months ended March 31, 2007 and 2006 was $963 and $3,032 and $648 and
$1,913, respectively, which consisted of stock-based compensation expense related to employee stock options and restricted stock awards.

11. RELATED
PARTY TRANSACTIONS

The Company received certain services from a former Chairman of the Board, James Bigl, as per a consulting agreement signed at the
end of his employment with the Company. James Bigl resigned as Chairman of the Board on March 13, 2006 but the consulting agreement continued until August 31, 2006. During the three months ended March 31, 2007 and 2006, $0 and $31 was
paid under this agreement, respectively. During the nine months ended March 31, 2007 and 2006, $64 and $95 was paid under this agreement, respectively. During the nine months ended March 31, 2007, the Company also paid approximately $5 of
legal fees on behalf of James Bigl.

In addition, the Company rents two houses from Living In Style, LLC, an entity partially owned by an executive officer
of the Company and a former Chairman of the Board, which is used for out-of-town employees. The leases are dated May 1, 2002 and expired on April 30, 2007. During the three months ended March 31, 2007 and 2006, the Company paid an
aggregate of $38 and $36 in rent for these two facilities, respectively. During the nine months ended March 31, 2007 and 2006, the Company paid an aggregate of $115 and $109 in rent for these two facilities, respectively.



18



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(All in thousands, except share amounts)

(UNAUDITED)



12. SUPPLEMENTAL CASH FLOW INFORMATION

During the nine months ended March 31, 2007 and 2006, the Company paid $185 and $340 in interest, and $446 and $1,079 in income taxes, respectively. During the nine months ended March 31, 2007, the Company
financed $89 for the acquisition of MPP through its trade payables. In addition, as of March 31, 2007, the Company financed $5,118 of capital expenditures through capital lease obligations. On April 2, 2007, the Company paid $1,381 of
dividends on the series A preferred stock for the quarter ended March 31, 2007.

13. MAJOR CLIENTS AND PHARMACIES

For the nine months ended March 31, 2007 and 2006, approximately 19% and 24%, respectively, of the Companys revenue was from Mohawk Valley Physicians
Health Plan, Inc. (MVP), a client administering multiple plans, which is reported within the PBM segment. For the three months ended March 31, 2006, approximately 23% of the Companys revenue was from MVP.

On May 4, 2006, MVP notified the Company that they will not be renewing their contract with NMHC which expired on December 31, 2006.

For the three and nine months ended March 31, 2007 and 2006, approximately 20% and 14% and 11% and 10%, respectively, of the Companys revenue was from another
client, which is reported within the PBM segment. Amounts due from this client approximated $5,175 as of March 31, 2007.

For the three months ended
March 31, 2007, approximately 11% and 10% of the cost of claims was from two pharmacy chains. For the nine months ended March 31, 2007, approximately 12% of the cost of claims was from one pharmacy chain. Amounts payable to these pharmacy
chains approximated $7,082 and $6,799 as of March 31, 2007. For the three and nine months ended March 31, 2006, no pharmacy chain accounted for more than 10% of the total cost of claims.

14. COMMITMENTS AND CONTINGENCIES

The Company is currently involved
in various claims and legal proceedings and other disputes with third parties that arise from time to time in the ordinary course of business. The Company has considered these proceedings and disputes in determining the necessity of any reserves for
losses that are probable and reasonably estimable in accordance with SFAS No. 5, Accounting for Contingencies. The Companys recorded reserves are based on estimates developed with consideration given to the potential merits of
claims, the range of possible settlements, advice from outside counsel, and managements strategy with regard to the settlement of such claims or defense against such claims. While the ultimate outcome of those claims and lawsuits which
currently are pending cannot be predicted with certainty, the Company believes, based on its understanding of the facts of these claims and proceedings, that their ultimate resolution will not, in the aggregate, have a material adverse effect on the
Companys financial position, results of operations or cash flows.



19



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations

Overview

We provide comprehensive PBM services to plan clients, which include managed care organizations, local governments, unions, corporations and third
party health care plan administrators through our network of licensed pharmacies throughout the United States. Our PBM services include electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail service pharmacy
claims management, specialty pharmacy claims management, benefit design consultation, preferred drug management programs, drug review and analysis, consulting services, disease information services, data access, reporting and information analysis,
and physician profiling. We also provide a mail service pharmacy and a specialty pharmacy program for our clients and individual patients.

With the
acquisition and significant growth of Ascend, we have two reportable segments, PBM and Specialty Pharmacy. The PBM segment includes the sale of traditional prescription drugs to our clients and their participants, either through our nationwide
network of pharmacies or our mail service pharmacy. The Specialty Pharmacy segment includes the sale of higher margin specialty pharmacy products and services for the treatment of chronic and potentially life-threatening diseases. Both the PBM and
Specialty Pharmacy segments operate in the United States and its territories.

The pharmacy benefit management industry is intensely competitive, generally
resulting in continuous pressure on our gross profit as a percentage of total revenue. In recent years, industry consolidation and dramatic growth in managed healthcare have led to increasingly aggressive pricing of pharmacy benefit management
services. Given the pressure on all parties to reduce healthcare costs, we expect this competitive environment to continue for the foreseeable future.

OPERATING INCOME

Three Months Ended March 31,



|                                             |  |      |         |   |                      |        |    |      |   |        
|-------------------------------------------- |  | ---- | ------- | - | -------------------- | ------ | -- | ---- | - | -------
|                                             |  | 2007 |         |   | Increase/ (Decrease) |        |    | 2006
|Revenue                                      |  | $    | 145,026 |   |                      | (33.1  | )% |      | $ | 216,801
|Cost of claims                               |  |      | 123,700 |   |                      | (36.4  | )% |      |   | 194,381
|                                             |  |      |         |   |                      |        |    |      |   |        
|Gross profit                                 |  |      | 21,326  |   |                      | (4.9   | )% |      |   | 22,420 
|Selling, general and administrative expenses |  |      | 21,402  |   |                      | 10.8   | %  |      |   | 19,308 
|                                             |  |      |         |   |                      |        |    |      |   |        
|Operating (loss) income                      |  | $    | (76     | ) |                      | (102.4 | )% |      | $ | 3,112  
|                                             |  |      |         |   |                      |        |    |      |   |        
|OPERATING INCOME Nine Months Ended March 31,
|                                             |  | 2007 |         |   | Increase/ (Decrease) |        |    | 2006
|Revenue                                      |  | $    | 533,043 |   |                      | (18.2  | )% |      | $ | 651,402
|Cost of claims                               |  |      | 466,819 |   |                      | (19.8  | )% |      |   | 581,742
|                                             |  |      |         |   |                      |        |    |      |   |        
|Gross profit                                 |  |      | 66,224  |   |                      | (4.9   | )% |      |   | 69,660 
|Selling, general and administrative expenses |  |      | 61,446  |   |                      | 8.0    | %  |      |   | 56,897 
|                                             |  |      |         |   |                      |        |    |      |   |        
|Operating income                             |  | $    | 4,778   |   |                      | (62.6  | )% |      | $ | 12,763 
|                                             |  |      |         |   |                      |        |    |      |   |        



20



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

Results of
Operations

Three Months Ended March 31, 2007 Compared to Three Months Ended March 31, 2006

Revenue decreased $71,775, or 33.1%, from $216,801 for the three months ended March 31, 2006 to $145,026 for the three months ended March 31, 2007. The decrease
in revenue is primarily the result of a decrease in covered lives during the three months ended March 31, 2007 as compared to the three months ended March 31, 2006.

Cost of claims decreased $70,681, or 36.4%, from $194,381 for the three months ended March 31, 2006 to $123,700 for the three months ended March 31, 2007. This decrease is primarily the result of a decrease
in covered lives during the three months ended March 31, 2007 as compared to the three months ended March 31, 2006. As a percentage of revenue, cost of claims decreased from 89.7% to 85.3% for the three months ended March 31, 2006 and
March 31, 2007, respectively.

Gross profit decreased $1,094, or 4.9%, from $22,420 for the three months ended March 31, 2006 to $21,326 for the
three months ended March 31, 2007. This decrease is primarily the result of a $1,686 reduction from our PBM segment primarily related to a $2,689 reduction in rebate revenue due to the current trends in negotiations with our clients offset by
improved changes in our client mix. This decrease was partially offset by a $592 increase in gross profit from our Specialty segment. Gross profit, as a percentage of revenue, increased from 10.3% to 14.7% for the three months ended March 31,
2006 and March 31, 2007, respectively.

Selling, general and administrative expenses increased $2,094, or 10.8%, from $19,308 for the three months
ended March 31, 2006 to $21,402 for the three months ended March 31, 2007. This increase is primarily the result of i) $1,491 net increase in compensation and related items, ii) $466 net increase in professional fees and insurance, and
iii) $137 net increase in other selling, general and administrative expenses.

Selling, general and administrative expenses as a percent of revenue
increased from 8.9% for the three months ended March 31, 2006 to 14.8% for the three months ended March 31, 2007.

Other income, net decreased
$55, or 14.1%, from $389 for the three months ended March 31, 2006 to $334 for the three months ended March 31, 2007. The decrease primarily relates to additional interest expense incurred during the three months ended March 31, 2007
in relation to the financing of various capital leases.

Income before (benefit) provision for income taxes decreased $3,243, or 92.6%, from $3,501 for the
three months ended March 31, 2006 to $258 for the three months ended March 31, 2007. The decrease primarily relates to i) $2,094 increase in our selling, general and administrative expenses, ii) $1,094 decrease in our gross profit, and
iii) $55 decrease in other income as noted above.

Our effective tax rate was (66.7%) for the three months ended March 31, 2007 as compared to
42.6% for the three months ended March 31, 2006. The decrease in the effective tax rate for the three months ended March 31, 2007 primarily resulted from a $439 reversal of a prior state tax reserve as the related statute of limitations
expired during the quarter ended March 31, 2007 offset by lower pre-tax income combined with the effects of expensing employee stock options in accordance with SFAS No. 123(R).

Net income decreased $1,578, or 78.6%, from $2,008 for the three months ended March 31, 2006 to $430 for the three months ended March 31, 2007. The decrease is
primarily the result of i) the decrease in gross profit, ii) the increase in selling, general and administrative expenses, and iii) the decrease in other income. These decreases were offset by the recognition of a $172 benefit from income taxes for
the three months ended March 31, 2007 as compared to a $1,493 provision for income taxes for the three months ended March 31, 2006.



21



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

In addition, there
were two charges against net income available to common stockholders related to the New Mountain Transaction (see Liquidity and Capital Resources). The first of these charges relates to series A preferred stock cash dividends, which
amounted to $1,381 for both three months ended March 31, 2007 and 2006. The series A preferred stock provides for an initial cash dividend equal to 7% of the investment amount (currently $80,000), which decreases to 3.5% after the fifth
anniversary of issuance, March 19, 2009. The dividend of $1,381 represents the amount accrued and paid for the three months ended March 31, 2006. The dividend of $1,381 represents the amount accrued for the three months ended
March 31, 2007. However, this dividend was not paid until April 2, 2007. The second charge is for the accretion of transaction expenses which was $117 for both three months ended March 31, 2007 and 2006.

After deducting these two charges from net income, there remained net income (loss) available to common stockholders of $(1,068) for the three months ended
March 31, 2007 as compared to $510 for the three months ended March 31, 2006.

Nine Months Ended March 31, 2007 Compared to Nine
Months Ended March 31, 2006

Revenue decreased $118,359, or 18.2%, from $651,402 for the nine months ended March 31, 2006 to $533,043 for
the nine months ended March 31, 2007. The decrease in revenue is primarily the result of a decrease in covered lives during the nine months ended March 31, 2007 as compared to the nine months ended March 31, 2006.

Cost of claims decreased $114,923, or 19.8%, from $581,742 for the nine months ended March 31, 2006 to $466,819 for the nine months ended March 31, 2007. This
decrease is primarily the result of decrease in covered lives during the nine months ended March 31, 2007 as compared to the nine months ended March 31, 2006. As a percentage of revenue, cost of claims decreased from 89.3% to 87.6% for the
nine months ended March 31, 2006 and March 31, 2007, respectively.

Gross profit decreased $3,436, or 4.9%, from $69,660 for the nine months
ended March 31, 2006 to $66,224 for the nine months ended March 31, 2007. This decrease is primarily the result of a $5,676 reduction in rebate revenue from our PBM segment (exclusive of the $1,017 Rebate Error as defined and discussed in
our Quarterly Report on Form 10-Q for the period ended September 30, 2006 (First Quarter 10-Q)) due to the current trends in negotiations with our clients offset by improved changes in our client mix. This decrease was partially
offset by i) $506 net increase which consists of $1,523 relating to the Claims Payable Error as defined and discussed in the First Quarter 10-Q offset by $1,017 relating to the Rebate Error as noted above, ii) $794 increase in gross profit from our
PBM segment, exclusive of rebates and iii) $940 increase in gross profit from our Specialty segment. Primarily due to the improved changes in our client mix, gross profit, as a percentage of revenue, increased from 10.7% to 12.4% for the nine months
ended March 31, 2006 and March 31, 2007, respectively.

Selling, general and administrative expenses increased $4,549, or 8.0%, from $56,897 for
the nine months ended March 31, 2006 to $61,446 for the nine months ended March 31, 2007. This increase is primarily the result of i) $2,787 net increase in compensation and related items, ii) $1,956 increase in professional fees and
insurance, and iii) $831 increase related to the Claims Payable Error as noted above. These increases were offset by $584 related to the Lease Error as defined and discussed in the First Quarter 10-Q and $441 of net reductions in other selling,
general and administrative expenses.

Selling, general and administrative expenses as a percent of revenue increased from 8.7% for the nine months ended
March 31, 2006 to 11.5% for the nine months ended March 31, 2007.

Other income, net increased $129, or 16.4%, from $787 for the nine months
ended March 31, 2006 to $916 for the nine months ended March 31, 2007. The increase primary relates to a $192 increase in interest income earned from higher interest rates and on higher cash balances for the nine months ended
March 31, 2007. This increase was offset by $104 of additional interest expense incurred during the nine months ended March 31, 2007 primarily related to the financing of various capital leases.



22



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

Income before
(benefit) provision for income taxes decreased $7,856, or 58.0%, from $13,550 for the nine months ended March 31, 2006 to $5,694 for the nine months ended March 31, 2007. The decrease primarily relates to the $3,436 decrease in our gross
profit as well as the $4,549 increase in our selling, general and administrative expenses, offset by the $129 net increase in other income as noted above.

Our effective tax rate was 41.1% for the nine months ended March 31, 2007 as compared to 42.6% for the nine months ended March 31, 2006. The decrease in the effective tax rate for the nine months ended March 31, 2007
primarily resulted from a $439 reversal of a prior state tax reserve as the related statute of limitations expired during the quarter ended March 31, 2007 offset by lower pre-tax income combined with the effects of expensing employee
stock options in accordance with SFAS No. 123(R).

Net income decreased $4,418, or 56.8%, from $7,773 for the nine months ended March 31, 2006 to
$3,355 for the nine months ended March 31, 2007. The decrease is primarily the result of i) the decrease in gross profit, ii) the increase in selling, general and administrative expenses, offset by i) the decrease in our effective tax rate from
42.6% for the nine months ended March 31, 2006 to 41.1% for the nine months ended March 31, 2007 and ii) the increase in other income.

In
addition, there were two charges against net income available to common stockholders related to the New Mountain Transaction (see Liquidity and Capital Resources). The first of these charges relates to series A preferred stock cash
dividends, which amounted to $4,204 for both nine months ended March 31, 2007 and 2006. The series A preferred stock provides for an initial cash dividend equal to 7% of the investment amount (currently $80,000), which decreases to 3.5% after
the fifth anniversary of issuance, March 19, 2009. The dividends of $4,204 represents the amount accrued and paid for the nine months ended March 31, 2006. The dividends of $4,204 represents the amount accrued for the nine months ended
March 31, 2007. However, $1,381 of this dividend was not paid until April 2, 2007. The second charge is for the accretion of transaction expenses which was $356 for both nine months ended March 31, 2007 and 2006.

After deducting these two charges from net income, there remained net income (loss) available to common stockholders of $(1,205) for the nine months ended March 31,
2007 as compared to $3,213 for the nine months ended March 31, 2006.

Liquidity and Capital Resources

Our primary cash requirements are for capital expenditures and operating expenses, including cost of pharmaceuticals, software and hardware upgrades, funding of accounts
receivable and inventory in our mail service facility and specialty pharmacy. Also, we require cash to execute our strategy of pursuing acquisitions of specialty pharmacy businesses and PBM businesses meeting specific criteria. We have acquired
seven companies since July 2000 utilizing primarily cash. This has had the effect of increasing our working capital deficits until sufficient profitability is earned to offset these deficits. As of March 31, 2007, we had a working capital
deficit of $2,909 as compared to a working capital deficit of $7,098 as of June 30, 2006.

As a result of our normal payment cycle, cash disbursement
accounts carrying negative book balances of $2,429 and $11,015 (representing outstanding checks not yet presented for payment) have been reclassified to claims payable to pharmacies, rebates payable to clients and trade and other payables and
accrued expenses as of March 31, 2007 and June 30, 2006, respectively. This reclassification restores balances to cash and current liabilities for liabilities to our vendors, clients and participants which have not cleared. No
overdraft or unsecured short-term loan exists in relation to these negative balances.



23



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

We have invested
substantial amounts of time and resources to our Medicare drug benefit program. In order for us to maintain our licensures and continue to apply for licensure in the various states, we must fulfill statutory capital and surplus requirements. We
currently maintain $6,559 in a cash account to fulfill such requirements. We expect the total funding requirements in order to fulfill statutory capital and surplus requirements in various states to approximate $14,000. We may not be able to realize
any return on our investments in Medicare initiatives if the cost and complexity of recent changes by and requirements of CMS exceed our expectations or prevent effective program implementation; if the government alters or reduces funding of
Medicare programs because of the higher-than-anticipated cost to taxpayers of the Medicare Modernization Act of 2003 (MMA) or for other reasons; if we fail to become a risk bearing entity prior to the expiration of the CMS waivers for
the 43 other states and territories; or if we fail to design and maintain programs that are attractive to our clients or individual Medicare participants; or if we are not successful in retaining employer groups and their enrollees, or if CMS does
not renew our contract.

Net cash provided by operating activities was $5,654 for the nine months ended March 31, 2007 as compared to $7,289 for the
nine months ended March 31, 2006. This decrease of $1,635 is primarily the result of a $23,362 decrease in rebates receivable from manufacturers, a $10,751 decrease in accounts receivable and a $11,660 increase in trade and other payables and
accrued expenses. These decreases were partially offset by a $23,234 decrease in claims payable to pharmacies and a $18,996 decrease in rebates payable to clients. This decrease was further caused by $1,908 of net decreases in other operating
activities.

Historically, the timing of our collections of accounts receivable and payments of accounts payable has generally been a net source of cash
from operating activities. This is the result of the terms of trade in place with plan clients on the one hand, and our pharmacy network on the other hand. These terms generally lead to our payments to participating pharmacies being slower than our
corresponding collections from plan clients. We believe that this situation is not unusual in the pharmacy benefit management industry and expect to operate on similar terms for the foreseeable future. However, there can be no assurance that such
terms of trade will continue in the future and, if they were to change materially, we could require additional working capital financing. We have put in place a $65,000 revolving credit facility for acquisitions and working capital financing.
However, if such terms of trade were to change materially, and/or if we were unable to obtain additional working capital financing, there could be a material adverse effect on our business, financial condition, or results of operations. Subsequent
to December 31, 2006, we notified JPMorgan that we did not timely file our Quarterly Report on Form 10-Q for the period ended December 31, 2006 (Second Quarter 10-Q), and requested temporary waivers of the relevant provisions
of our credit agreement arising from the failure to timely file the Second Quarter 10-Q. On February 16, 2007, we received a waiver to our credit agreement with JPMorgan, to temporarily waive certain relevant provisions of the credit agreement
arising from the failure to timely file the First Quarter 10-Q and the Second Quarter 10-Q. As a result, we were entitled to borrow up to $20,000 pursuant to the credit agreement until March 31, 2007. Among other things, the wavier required us
to provide a certificate of a financial officer and other items to the lenders on or before March 31, 2007. We provided these items to the lenders prior to March 31, 2007 which allowed us to regain complete access to borrow up to $65,000
pursuant to our credit agreement, subject to standard conditions and requirements.

Net cash used in investing activities was $5,189 for the nine months
ended March 31, 2007 as compared to $6,010 for the nine months ended March 31, 2006. The $5,189 net cash used in investing activities for the nine months ended March 31, 2007 was primarily the result of $4,027 used for capital
expenditures, $901 used for an earnout payment to PPP and $266 used for the acquisition of MPP.

Net cash used in financing activities was $3,255 for the
nine months ended March 31, 2007 as compared to $1,693 of net cash provided by financing activities for the nine months ended March 31, 2006. This decrease of $4,948 is primarily the result of i) the Company paying an additional $2,269
towards their capital lease obligations during the nine months ended March 31, 2007, ii) $2,823 reduction in the proceeds from the



24



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

exercise of stock
options, and iii) $1,237 reduction in the excess tax benefit from the exercise of stock options. These decreases were offset by the Company not paying $1,381 of dividends on the series A preferred stock for the quarter ended March 31, 2007
until April 2, 2007.

EBITDA

On January 28,
2005, we entered into a five-year $65,000 line of credit with a syndicate of commercial banks led by JPMorgan. Subject to certain conditions, the line of credit may be increased by an aggregate of $35,000. The line of credit contains various
covenants that, among other things, require us to maintain certain financial ratios, which are consolidated net worth, consolidated fixed charge ratio and consolidated debt to EBITDA (earnings before interest, taxes, depreciation and amortization)
ratio. The consolidated fixed charge ratio and the consolidated debt to EBITDA ratio are evaluated by JPMorgan as a measure of our liquidity and our ability to meet all of our obligations under the credit facility. As of March 31, 2007, we were
in compliance with the aforementioned financial covenants.

We calculate and use EBITDA and EBITDA per adjusted prescription as indicators of our ability
to generate cash from our reported operating results. These measurements are used in concert with net income and cash flows from operations, which measure actual cash generated in the period. In addition, we believe that EBITDA and EBITDA per
adjusted prescription are supplemental measurement tools used by analysts and investors to help evaluate overall operating performance and the ability to incur and service debt and make capital expenditures. EBITDA does not represent funds available
for our discretionary use and is not intended to represent or to be used as a substitute for net income or cash flows from operations data as measured under generally accepted accounting principles. The items excluded from EBITDA but included in the
calculation of our reported net income are significant components of our consolidated statements of income, and must be considered in performing a comprehensive assessment of our overall financial performance. EBITDA, and the associated year-to-year
trends, should not be considered in isolation. Our calculation of EBITDA may not be consistent with calculations of EBITDA used by other companies.

EBITDA
per adjusted prescription is calculated by dividing EBITDA by the adjusted prescription volume for the period. This measure is used as an indicator of our EBITDA performance on a per-unit basis, providing insight into the cash-generating potential
of each prescription. EBITDA per adjusted prescription reflects the level of efficiency in the business and is affected by changes in prescription volumes between retail and mail, as well as the relative representation of brand-name, generic and
specialty drugs.

Net cash provided by operating activities can be reconciled to EBITDA, which we believe to be the most directly comparable financial
measure to net cash provided by operating activities, as follows:



|                                                                   |  |                             |        |   |      |   |        |  
|------------------------------------------------------------------ |  | --------------------------- | ------ | - | ---- | - | ------ | -
|                                                                   |  | Nine Months Ended March 31, |       
|                                                                   |  | 2007 (1)                    |        |   | 2006 |  
|Net cash provided by operating activities                          |  | $                           | 5,654  |   |      | $ | 7,289  |  
|Provision for income taxes                                         |  |                             | 2,339  |   |      |   | 5,777  |  
|Interest (income) expense, net                                     |  |                             | (895   | ) |      |   | (807   | )
|Net change in assets and liabilities                               |  |                             | 10,289 |   |      |   | 8,461  |  
|Non-cash items to reconcile net cash from operations to net income |  |                             | (5,480 | ) |      |   | (2,578 | )
|                                                                   |  |                             |        |   |      |   |        |  
|EBITDA                                                             |  | $                           | 11,907 |   |      | $ | 18,142 |  
|                                                                   |  |                             |        |   |      |   |        |  
|Adjusted prescriptions (2)                                         |  |                             | 19,361 |   |      |   | 25,633 |  
|EBITDA per adjusted prescription                                   |  | $                           | 0.61   |   |      | $ | 0.71   |  

---

|(1) | During the quarter ended March 31, 2007, we did not pay $1,381 of dividends on the series A preferred stock until April 2, 2007. During the quarter ended
March 31, 2006, we paid $1,381 of dividends on the series A preferred stock.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(2) | Estimated adjusted prescription volume equals prescriptions processed at our mail service facility multiplied by 3, plus retail prescriptions. The prescriptions processed at our
mail service facility are multiplied by 3 to adjust for the fact that they typically include approximately 3 times the amount of product days supplied compared with retail prescriptions.
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



25



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(All in thousands, except share amounts)

(UNAUDITED)



Off-Balance Sheet Arrangements

None.

Contractual Obligations

We lease offices and warehouse space throughout the United States under various operating leases. The Company also leases pill dispensing and counting devices for use in its mail service pharmacy, as well as computer equipment for use in
its various offices.

In addition, we rent two houses from Living In Style, LLC, an entity partially owned by an executive officer of the Company and a
former Chairman of the Board, which is used for out-of-town employees. We evaluated the cost of hotels for these out-of-town employees and determined that it was more cost efficient to rent the houses.

The following table summarizes scheduled maturities of our contractual obligations for which cash flows are fixed and determinable as of March 31, 2007:

Payments Due by Period



|                                   |  |       |        |      |   |           |  |           |       |            |   |       |  |   |      
|---------------------------------- |  | ----- | ------ | ---- | - | --------- |  | --------- | ----- | ---------- | - | ----- |  | - | -----
|                                   |  | Total |        | 2007 |   | 2008-2009 |  | 2010-2011 |       | Thereafter
|Capital Lease Obligations          |  | $     | 2,845  |      | $ | 1,125     |  | $         | 1,505 |            | $ | 215   |  | $ |     
|Operating Leases                   |  | $     | 10,818 |      | $ | 3,571     |  | $         | 3,940 |            | $ | 1,818 |  | $ | 1,489
|                                   |  |       |        |      |   |           |  |           |       |            |   |       |  |   |      
|Total Contractual Cash Obligations |  | $     | 13,663 |      | $ | 4,696     |  | $         | 5,445 |            | $ | 2,033 |  | $ | 1,489
|                                   |  |       |        |      |   |           |  |           |       |            |   |       |  |   |      

Commitments and Contingencies

As an approved prescription drug plan (PDP) sponsor, our subsidiary, NMHC Group Solutions, began offering a PDP under Medicare Part D to individual enrollees and employer groups on January 1, 2007.
NMHC Group Solutions entered into a formal agreement with CMS on October 13, 2006 to operate as a national PDP sponsor. Under regulations established by CMS governing participation in the Medicare Part D program and state regulations, NMHC
Group Solutions must be licensed as a risk-bearing entity regulated under state insurance laws and must obtain licensure as a domestic insurance company. NMHC Group Solutions has been approved to operate as a risk-bearing entity in its domicile
state, Delaware, and has filed applications for licensure in the 49 other states and Washington D.C., and Puerto Rico. NMHC Group Solutions is currently acting as a risk-bearing entity for individual enrollees in its PDP. We are at various stages
with these applications in the ancillary states and have obtained licensure in eight additional states to operate as a risk-bearing entity. We are currently operating under a three-year waiver granted by CMS for the states and territories which have
not issued us a risk-



26



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

bearing license. In
order for NMHC Group Solutions to maintain its licensures and continue to apply for licensure in the various states, it must fulfill statutory capital and surplus requirements. NMHC Group Solutions currently maintains $6,559 in a cash account to
fulfill such requirements. We expect the total funding requirements to fulfill statutory capital and surplus requirements in various states to approximate $14,000.

Certain of our business acquisition agreements include earn-out provisions. These provisions generally require that we pay to the seller or sellers of the business additional amounts based on the performance of the acquired
business. Since the size of each payment depends upon performance of the acquired business, we do not expect that such payments will have a material adverse impact on our future results of operations or financial condition.

We entered into an amended and restated preferred stock purchase agreement, dated as of November 26, 2003, with New Mountain Partners, L.P. (the purchase
agreement). Pursuant to the purchase agreement, we agreed, subject to various conditions, to issue to New Mountain Partners a total of 6,956,522 shares of the series A preferred stock at a purchase price of $11.50 per share, for aggregate
proceeds of approximately $80,000. On March 19, 2004, we completed the sale of the series A preferred stock to New Mountain Partners and used approximately $49,000 of the proceeds of the sale of the series A preferred stock to
purchase, pursuant to a tender offer, 4,448,900 shares of our outstanding common stock at $11.00 per share (collectively, the New Mountain Transaction).

Following the completion of the tender offer, New Mountain Partners owned securities at March 19, 2004 that were initially convertible into approximately 64% of our issued and outstanding common stock and prior
to conversion of the series A preferred stock were entitled to cast that number of votes that is equal to approximately 60% of our aggregate voting power. Following the closing of the New Mountain transaction, New Mountain Partners was entitled
to and did nominate and elect 60% of the members of our board of directors.

We used the remaining proceeds from the issuance and sale of the series A
preferred stock of approximately $24,000, excluding expenses related to the closing of the New Mountain Transaction, for the Inteq acquisition and working capital purposes.

The series A preferred stock provides for an initial annual cash dividend equal to 7% of the investment amount, which decreases to 3.5% after the fifth anniversary of issuance. The series A preferred stock is
convertible into common stock at a price of $11.50 per share of common stock, or an aggregate of 6,956,522 shares of our common stock.

The series A
preferred stock may be redeemed at our option subsequent to the fourth anniversary of its issuance, subject to certain conditions. Subject to certain conditions, after the fourth anniversary of its issuance, we can redeem shares of the series A
preferred stock at its reported value on our consolidated balance sheet plus all unpaid dividends, whether or not declared. Subject to certain conditions, after the seventh anniversary of its issuance, we can redeem shares of series A preferred
stock at $11.50 per share plus all unpaid dividends, whether or not declared. After the tenth anniversary of the issuance of the series A preferred stock, each holder of shares of series A preferred stock may require us to redeem all or a
part of that holders shares of series A preferred stock. Each holder of shares of series A preferred stock can redeem their series A preferred stock at $11.50 per share plus all unpaid dividends, whether or not declared.

Subject to certain conditions, the liquidation value of the series A preferred stock is the greater of $11.50 per share plus all unpaid dividends, whether or not
declared, or the amount that would be payable to a holder of the series A preferred stock if the series A preferred stock was converted into common stock immediately prior to the liquidation.



27



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

We anticipate that
current cash positions, together with anticipated cash flow from operations, will be sufficient to satisfy our contemplated cash requirements for at least 24 months. This is based upon current levels of capital expenditures and anticipated operating
results for the next 24 months. However, it is one of our stated goals to acquire specialty pharmacy businesses and PBM businesses meeting specific criteria. Depending on our evaluation of future acquisitions, additional cash may be required to
complete these acquisitions. In addition, we will require cash to acquire inventory for our mail service and specialty service operations, and fulfill statutory capital and surplus requirements in connection with our PDP. In the event that our plans
change or our assumptions prove to be inaccurate, or our cash on hand together with the proceeds from our revolving credit facility prove to be insufficient to fund operations and acquisitions, we could be required to seek additional financing
sooner than anticipated. There can be no assurance that such financing could be obtained at rates or on terms acceptable to us, if at all.

For the nine
months ended March 31, 2007 and 2006, approximately 19% and 24%, respectively, of our revenue was from Mohawk Valley Physicians Health Plan, Inc. (MVP), a client administering multiple plans, which is reported within the PBM
segment. For the three months ended March 31, 2006, approximately 23% of our revenue was from MVP.

On May 4, 2006, MVP notified us that they
will not be renewing their contract with us which expired on December 31, 2006.

Other Matters

Inflation

Changes in prices charged by manufacturers and
wholesalers for pharmaceuticals affect our revenue and cost of claims.

Critical Accounting Policies and Estimates

General

Our discussion and analysis of our financial condition
and results of operations are based upon our unaudited consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these financial statements requires us
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Our estimates and assumptions
are based upon a combination of historical information and various other assumptions believed to be reasonable under the particular circumstances. Actual results may differ from our estimates.

We believe that of our significant accounting policies (See Note 2 to the Consolidated Financial Statements comprising Item 8 of Form 10-K for the year ended
June 30, 2006), the following may involve a higher degree of judgment and complexity than others:

Revenue Recognition Our revenue
primarily consists of sales of prescription drugs, together with any associated administrative fees, to clients and participants, either through our nationwide network of pharmacies, our mail service pharmacy or our specialty pharmacy. We enter into
a fee for service (per claim charges) arrangement with our clients for the payment of administrative fees. Under the fee for service arrangement, we are paid by our clients for our contractually agreed upon rates based upon actual claims adjudicated
plus a fixed transaction fee. Revenue related to the sales of prescription drugs by our nationwide network of pharmacies, our mail service pharmacy or specialty pharmacy, is recognized when the claims are adjudicated and the prescription drugs are
shipped. Co-payment revenue recognized during the three months ended March 31, 2007 and 2006 was $4,210 and $4,728, respectively. Co-payment revenue recognized



28



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

during the nine
months ended March 31, 2007 and 2006 was $12,649 and $13,846, respectively. Claims are adjudicated at the point-of-sale using our on-line processing system. To date, our mail service pharmacy primarily fills prescriptions for our plan clients.
Revenue from these intercompany sales is eliminated in consolidation. Specialty pharmacy revenues represent revenues from the sale of primarily biopharmaceutical drugs and are reported at the net amount billed to third-party payors, patients and
others. For the nine months ended March 31, 2007, approximately 53% of revenues from our specialty pharmacy are from prescriptions filled for our plan clients. Revenue from these intercompany sales is eliminated in consolidation. The remaining
47% of revenues from our specialty pharmacy are recognized at the point of shipment.

Participant co-payments are not recorded as revenue. Under our client
contracts, the pharmacy is solely obligated to collect the co-payments from the participants. Under client contracts, we do not assume liability for participant co-payments in pharmacy transactions. As such, we do not include participant co-payments
to pharmacies in revenue or cost of claims. For the three months ended March 31, 2007 and 2006, excluded from our revenue and cost of claims was $53,393 and $82,544, respectively, of participant co-payments to pharmacies. For the nine months
ended March 31, 2007 and 2006, excluded from our revenue and cost of claims was $198,683 and $243,043, respectively, of participant co-payments to pharmacies. If the above amounts were included in our revenue and cost of claims, our operating
income, net income, consolidated balance sheets and statements of cash flows would not have been affected.

We evaluate client contracts using the
indicators of Emerging Issues Task Force (EITF) No. 99-19, Reporting Gross Revenue as a Principal vs. Net as an Agent, to determine whether we act as a principal or as an agent in the fulfillment of prescriptions through
the retail pharmacy network. We act as a principal in most of our transactions with clients and revenues are recognized at the prescription price (ingredient cost plus dispensing fee) negotiated with clients, as well as our administrative fees
(Gross Reporting). Gross reporting is appropriate because we (a) have separate contractual relationships with clients and with pharmacies, (b) are responsible to validate and economically manage a claim through our claims
adjudication process, (c) commit to set prescription prices for the pharmacy, including instructing the pharmacy as to how that price is to be settled (co-payment requirements), (d) manage the overall prescription drug plan relationship
with the patients, who are participants of clients plans, and (e) have credit risk for the price due from the client. There are certain contracts in which the Company recognizes revenue on a net basis. The primary factor that leads to
recognizing net revenue on these contracts is that the amount the Company earns is primarily fixed. Whether revenues are recorded on either a gross or net basis, we record the gross amount billed in accounts receivable and the related claims payable
to pharmacies on our consolidated balance sheets.

The rebates and administrative fees (pharmaceutical manufacturer payments) that we receive
from pharmaceutical manufacturers are recognized when we are entitled to them in accordance with the terms of our arrangements with pharmaceutical manufacturers, third party rebate administrators, and our clients, and when the amount of the
pharmaceutical manufacturer payment is determinable. Our rebate revenue is reduced by the estimated amount of pharmaceutical manufacturer payments that our clients are entitled to. We compute the estimated amount of pharmaceutical manufacturer
payments due direct from the drug manufacturers based on the actual claims, estimated market data and the criteria established in each individual contract. The drug manufacturers are obligated to reimburse us for earned pharmaceutical manufacturer
payments within a specified period of time. We reconcile our estimates to amounts received from the manufacturers on a quarterly basis. Certain of our clients are contractually entitled to all or a portion of the pharmaceutical manufacturer payments
we receive. For the three months ended March 31, 2007 and 2006, the pharmaceutical manufacturer payments retained by us have approximated 11.2% and 21.4%, respectively, of our total gross profit. For the nine months ended March 31, 2007
and 2006, the pharmaceutical manufacturer payments retained by us have approximated 11.9% and 20.6%, respectively, of our total gross profit. Based upon our client mix as well as trends in our negotiations with our clients, we expect pharmaceutical
manufacturer payments to continue to account for a declining percentage of our total gross profit.



29



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

Rebates We record the gross pharmaceutical manufacturer payment receivable and the appropriate payable to the clients based on estimates, which are subject to final settlement. The estimates are based upon claims
submitted and our pharmaceutical manufacturer payment experience, and are adjusted as additional information becomes available. Upon billing the manufacturer, any differences between our estimate and the actual amount of the pharmaceutical
manufacturer payments receivable is recorded to cost of claims, net of the estimated impact to our customers. Pharmaceutical manufacturer payments are generally paid to clients on a quarterly basis, or as agreed upon with our clients, subsequent to
collections from pharmaceutical manufacturers, although there are certain instances where pharmaceutical manufacturer payments are paid to clients on a more accelerated basis.

As of March 31, 2007 and June 30, 2006, total unbilled manufacturer receivables amounted to approximately $29.8 million and $23.5 million, respectively.

Allowance for Doubtful Accounts We maintain an allowance for doubtful accounts for estimated losses resulting from the liability of our clients to
make required payments. If the financial condition of our clients were to deteriorate, resulting in an impairment of their ability to make payments, an additional allowance may be required.

The allowance for doubtful accounts is based on a variety of factors, including the age of the outstanding receivable and the payors collection history. When
circumstances related to specific collection patterns change, estimates of the recoverability of receivables are adjusted.

Property and
Equipment We state property and equipment at cost, less accumulated depreciation and amortization. Equipment under capital leases is recorded at the present value of the total minimum lease payments. We calculate depreciation using the
straight-line method for assets with useful lives ranging from 3 to 8 years or, with respect to equipment under capital leases and leasehold improvements, we amortize them on the straight-line basis over the shorter of the lease term or the
assets useful lives.

Internal Use Software We invest heavily in developing software in order to enhance our operations as well
as meet the needs of our clients. We apply the provisions of the American Institute of Certified Public Accountants Statement of Position (SOP) 98-1, Accounting for the Costs of Computer Software Developed or Obtained for Internal
Use. Under this SOP, certain costs of computer software developed or obtained for internal use are capitalized and amortized on a straight-line basis over three years. Costs for general and administrative expenses, overhead, maintenance and
training, as well as the cost of software coding that does not add functionality to the existing system, are expensed as incurred. Reductions, if any, in the carrying value of capitalized software development costs to net realizable value are
expensed.

Intangible Assets Our intangible assets primarily reflect the value of client relationships that arose in connection with
our various business acquisitions. These intangible assets are recorded at cost and are reviewed for impairment whenever events, such as losses of significant clients or other changes in circumstances indicate that the carrying amount may not be
recoverable. We continually assess the useful lives of the intangible assets, taking into account historical client turnover experience, including recent losses of clients and expected future losses, to ensure they reflect current circumstances.

GoodwillOur goodwill represents the excess acquisition costs over the fair value of the net tangible and identifiable intangible
assets acquired that has been allocated to goodwill from our various business acquisitions. We test our goodwill for impairment on an annual basis, or whenever events, such as a protracted decline in our stock price or other changes in
circumstances, indicate that the carrying amount may not be recoverable, using a two-step fair-value based test. The most recent assessment of goodwill impairment for each of our designated reporting units was performed as of June 30, 2006, and
the recorded goodwill was determined not to be impaired.



30



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

Income
Taxes We account for income taxes in accordance with SFAS No. 109, Accounting for Income Taxes. This statement establishes financial accounting and reporting standards for the effects of income taxes that result
from an enterprises activities during the current and preceding years. It requires an asset and liability approach for financial accounting and reporting of income taxes. As of March 31, 2007, we have current net deferred tax assets
of $1,797 and non-current net deferred tax liabilities of $8,759. The net deferred tax assets assume sufficient future earnings for their realization, as well as the continued application of currently anticipated tax rates. We periodically
consider whether or not we should record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. While we have considered future taxable income and ongoing tax planning strategies in
assessing the need for the valuation allowance, in the event we were to determine that we would be able to realize our deferred tax assets in the future in excess of our net recorded amount, an adjustment to the deferred tax asset would increase
income in the period such determination was made. Likewise, should we determine that we would not be able to realize all or part of our net deferred tax asset in the future, an adjustment to the deferred tax asset would be charged to income in the
period such determination was made. Based on our assessment as of March 31, 2007, a valuation allowance is not required against our deferred tax assets.

Stock-Based CompensationWith the adoption of SFAS No. 123(R) on July 1, 2005, we are required to record the fair value of stock-based compensation awards as an expense. In order to determine the fair
value of stock options on the date of grant, we apply the lattice-binomial option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option life, risk-free interest rate, post-vesting terminations,
sub-optimal exercise factor and dividend yield. While the risk-free interest rate, post-vesting terminations, sub-optimal exercise factor and dividend yield are less subjective assumptions that are based on factual data derived from public
sources, the expected stock-price volatility and option life assumptions require a greater level of judgment which makes them critical accounting estimates.

We use an expected stock-price volatility assumption that is based on the historical volatility of the underlying stock which is obtained from public data sources. This approach is used as a predictor of future realized and implied
volatilities and is directly related to stock option valuation. For stock option grants issued during the nine months ended March 31, 2007, we used a weighted-average expected stock-price volatility of 58.2% based upon the historical
volatility at the time of issuance.

With regard to the weighted-average option life assumption, we consider the exercise behavior of past grants and model
the pattern of aggregate exercises. For stock option grants issued during the nine months ended March 31, 2007, we used a weighted-average expected option life assumption of 5.5 years.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We do not engage in significant activity with respect
to market risk sensitive instruments. Accordingly, our risk with respect to market risk sensitive instruments is immaterial.

Item 4. Controls and Procedures

As more fully defined and described in Item 2 - Managements Discussion and
Analysis of Financial Condition and Results of Operations in the First Quarter 10-Q, we identified misstatements primarily relating to our rebates payable to clients, our claims payable to pharmacies and our accounting treatment for leases.

In order to strengthen our internal controls, the Company is implementing a process whereby our Legal Department and our Account Management Department,
along with our Finance Department and Rebate and Formulary Group, will evaluate the terms and conditions for rebate payments to clients which will serve as the basis for payments to clients in the future. We are continuing the process of improving
our internal controls over the review and estimation process regarding the payment of rebates to our clients. For example, the Company is working on a procedure to track changes to contractual provisions relating to the



31



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

calculation of
rebates payable to clients. The Company has also implemented procedures for reviewing outstanding claims payable to pharmacies and for reviewing new leases to determine the proper accounting treatment in accordance with generally accepted accounting
principles.

Other than as described above, there have been no significant changes in our internal controls over financial reporting (as defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act) that occurred in this period that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

The Company will continue to evaluate the effectiveness of its internal controls and procedures on an ongoing basis and will implement further actions as necessary in
its continuing efforts to strengthen the internal control process.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are the controls and procedures designed to ensure that information that we are required to disclose in our reports under the
Securities Exchange Act of 1934, as amended (Exchange Act) is recorded, processed, summarized and reported within the time periods required. They include, without limitation, controls and procedures designed to ensure that information is
accumulated and communicated to management in order to allow timely decisions regarding required disclosure.

Under the supervision and with the
participation of management, chiefly our principal executive officer and our principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and
15d-15(e) under the Exchange Act), as of March 31, 2007. Our principal executive officer and our principal financial officer have concluded that as of March 31, 2007, these disclosure controls and procedures were not effective in alerting
them to material information, on a timely basis, required to be included in our periodic Securities and Exchange Commission filings. Based on that evaluation, the Company has adopted and is continuing to implement the additional procedures described
above.



32



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

PART II  OTHER INFORMATION

Item 1. Legal Proceedings

From time to time we become subject to legal proceedings and claims in the ordinary course of
business. Such claims, even if without merit, could result in the significant expenditure of our financial and managerial resources. While the ultimate outcome of those claims and lawsuits which currently are pending cannot be predicted with
certainty, we believe, based on our understanding of the facts of these claims and proceedings, that their ultimate resolution will not, in the aggregate, have a material adverse effect on our financial condition, results of operations or cash
flows.

Item 1A. Risk Factors

Our Annual Report on Form 10-K for the fiscal year ended June 30, 2006 includes a detailed
discussion of certain risk factors in Part I, Item 1A. The information presented below updates and should be read in conjunction with the risk factors and information disclosed in that Form 10-K. These are not the only risks and
uncertainties that we face. Additional risks and uncertainties that we do not currently know about or that we currently believe are immaterial, or that we have not predicted, may also harm our business operations or adversely affect us. If any of
these risks or uncertainties actually occurs, our business, financial condition, operating results or liquidity could be materially and adversely affected. In that event, the market price for our common stock could decline and you may lose your
investment. In addition to those risk factors, we note the following additional risk factors:

If we fail to develop or maintain an effective system
to monitor and settle our rebate and claims payable transactions, we may not be able to accurately report our financial results. As a result, current and potential shareholders could lose confidence in our financial reporting, which would harm our
business and the trading price of our common stock.

We currently do not have automated systems to monitor and settle our rebate and claims payable
transactions. Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud and to operate successfully as a public company. If we cannot provide reliable financial reports, our reputation and
operating results would be harmed. We have in the past discovered, and may in the future discover, areas of our internal controls, including with respect to our rebate and claims payable transactions, that need improvement. We have begun our
remediation efforts and we believe that our actions in this regard have strengthened our internal controls over financial reporting. See Managements Discussion and Analysis of Financial Condition and Results of Operations in
Part I, Item 2 in the First Quarter 10-Q and Controls and Procedures in Part I, Item 4 in this Form 10-Q.

Although
initiated, our plans to improve the effectiveness of our internal controls and processes are not yet complete. We anticipate that it will take some time to establish the disclosure controls and procedures desired by our management and our board of
directors. While we expect to complete this remediation process as quickly as possible, we cannot at this time estimate how long it will take to complete remediation. Professional fees incurred in connection with reviewing our existing controls and
procedures have been material. We may incur additional material costs in the future. We will continue to evaluate the effectiveness of the control environment and will continue to refine existing controls. We cannot assure you that the measures we
have taken to date or any future measures will remediate deficiencies in our internal controls. Additional deficiencies in our internal controls may be discovered in the future. Any failure to develop or maintain effective controls, or any
difficulties encountered in their implementation or improvement, could harm our operating results or cause us to fail to meet our reporting obligations and may result in a restatement of our prior period financial statements. Ineffective internal
controls could also cause investors to lose confidence in our reported financial information, which would likely have a negative effect on the trading price of our common stock.



33



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

In addition, these
deficiencies in internal controls that we identify in the future will need to be addressed as part of the evaluation of our internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 and may impair our
ability to comply with Section 404.

Due to the complex laws and regulations governing the Medicare program in which we participate, our
recorded estimates may materially change in the future, and our failure to fully comply with such laws and regulations may adversely impact our business and financial results.

The Medicare program in which we participate is based upon extremely complex laws and regulations that are subject to interpretation. As a result, there is at least a reasonable possibility that our recorded estimates
of receivables from CMS may change by a material amount in the near term. Additionally, our noncompliance with such laws and regulations could result in fines, penalties and exclusion from the Medicare program.

Although we are not aware of any allegations of noncompliance that could have a material adverse effect on our consolidated financial statements, we cannot assure you
that any instances of noncompliance will not have a material adverse effect on our financial statements or results of operations.

Changes in
industry pricing benchmarks could adversely affect our financial performance

Contracts in the prescription drug industry, including our contracts
with our retail pharmacy networks and with our PBM and Specialty pharmacy clients, generally use certain published benchmarks to establish pricing for prescription drugs. These benchmarks include average wholesale price (AWP), average
manufacturer price (AMP) and wholesale acquisition cost (WAC). Most of our contracts utilize the AWP standard. Recent events have raised uncertainties as to whether payors, pharmacy providers, PBMs and others in the
prescription drug industry will continue to utilize AWP as it has previously been calculated or whether other pricing benchmarks will be adopted for establishing prices within the industry. Specifically, in the recently announced proposed settlement
in the case of New England Carpenters Health Benefits Fund, et al. v. First DataBank, et al., Civil Action No. 1:05-CV-11148-PBS (D. Mass.), a civil class action case brought against First DataBank (FDB), one of several companies
that report data on prescription drug prices, FDB has agreed to reduce the reported AWP of certain drugs by four percent. At this time, the proposed settlement has received neither preliminary nor final court approval. We cannot predict the outcome
of this case, or, if the settlement is approved, the precise timing of any of the proposed AWP changes.

In the absence of any mitigating action on our
part, the proposed reduction in FDBs AWP would have a material adverse effect on the margin we earn on home delivery transactions. It may also create disruption in our retail networks due to the adverse impact on AWP-based retail pharmacy
pricing. However, most of our contracts with our clients and retail pharmacies contain terms that we believe will enable us to mitigate the adverse effect of this proposed reduction in FDBs reported AWP.

Whatever the outcome of the FDB case, we believe that payors, pharmacy providers and PBMs will begin to evaluate other pricing benchmarks as the basis for contracting
for prescription drugs and benefit management services in the future.



34



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

Due to these and
other uncertainties, we can give no assurance that the short or long term impact of changes to industry pricing benchmarks will not have a material adverse effect on our financial performance, results of operations and financial condition in future
periods.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Submission of Matters to a Vote of Security Holders

On April 17, 2007 we held our 2006 Annual Meeting of
Stockholders (the Annual Meeting). The holders of 5,471,365 shares of common stock and 6,956,522 shares of 7% series A redeemable convertible preferred stock were present in person or represented by proxy at the meeting. The following is
a summary of the results of the voting by our stockholders at the Annual Meeting.



| | 1. | Election of Directors
| | -- | ---------------------

The stockholders elected the
following persons to serve as directors of the Company for a term of one year. Votes were cast as follows:



|                     |  |                 |  |          
|-------------------- |  | --------------- |  | ---------
|                     |  | Number of Votes
|Name                 |  | For             |  | Withheld 
|James Smith          |  | 7,084,738       |  | 1,076,542
|Paul J. Konigsberg   |  | 8,076,067       |  | 85,213   
|Gerald Angowitz      |  | 8,057,067       |  | 86,213   
|Steven B. Klinsky    |  | 6,999,240       |  | 1,162,040
|Micheal B. Ajouz     |  | 7,084,738       |  | 1,076,542
|G. Harry Durity      |  | 7,084,738       |  | 1,076,542
|Michael T. Flaherman |  | 7,084,738       |  | 1,076,542
|Robert R. Grusky     |  | 7,084,738       |  | 1,076,542
|Thomas W. Erickson   |  | 8,148,455       |  | 12,825   
|Daniel B. Hebert     |  | 8,155,855       |  | 5,425    



| | 2. | The stockholders approved the appointment of Ernst & Young LLP as independent auditors for the fiscal year ending June 30, 2007. Votes were cast as follows:
| | -- | ------------------------------------------------------------------------------------------------------------------------------------------------------------



|          |  |         |  |        
|--------- |  | ------- |  | -------
|For       |  | Against |  | Abstain
|8,160,505 |  | 0       |  | 775    

A detailed description of the matters voted upon at the Registrants 2006 Annual Meeting of Stockholders has
been previously reported in NMHCs Definitive Proxy Statement filed with the SEC on March 28, 2007.



35



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)

Item 5. Other Information

2007 Annual Meeting Date; Deadlines for Stockholder Proposals

Our 2007 Annual Meeting of Stockholders will be held in December 2007.



| |  |  | Pursuant to Rule 14a-8 under the Exchange Act, the deadline for submitting stockholder proposals for inclusion in our proxy statement and form of proxy for the 2007
Annual Meeting is September 17, 2007, which we believe is a reasonable time before we will begin the printing and mailing of our proxy materials for the 2007 annual meeting.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | The date after which notice of a stockholder proposal submitted outside of the processes of Rule 14a-8 is considered untimely for purposes of Rule 14a-4(c)(1) under
the Exchange Act is October 1, 2007, which we believe is a reasonable time before we will begin the printing and mailing of our proxy materials for the annual meeting.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Stockholder proposals should be addressed to National Medical Health Card Systems Inc., Attention: Corporate Secretary, 26 Harbor Park Drive, Port Washington, NY, 11050.
It is recommended that stockholders submitting proposals use certified mail, return receipt requested in order to provide proof of timely receipt. We reserve the right to reject, rule out of order, or take other appropriate action with respect to
any proposal that does not comply with these and other applicable requirements, including conditions established by the SEC.

Item 6. Exhibits



|       |  |                                                                                                                                                        
|------ |  | -------------------------------------------------------------------------------------------------------------------------------------------------------
|Number |  | Description of Exhibit                                                                                                                                 
|3.1    |  | Certificate of Incorporation of NMHC (2)                                                                                                               
|       | 
|3.2    |  | Certificate of Amendment to the Certificate of Incorporation of NMHC (5)                                                                               
|       | 
|3.3    |  | Amended and Restated Bylaws of NMHC (5)                                                                                                                
|       | 
|3.4    |  | Amended and Restated Audit Committee Charter (5)                                                                                                       
|       | 
|3.5    |  | Amendment No. 1 to Amended and Restated By-Laws of NMHC (9)                                                                                            
|       | 
|3.6    |  | Nominating and Corporate Governance Committee Charter (6)                                                                                              
|       | 
|4.1    |  | Form of Warrant Agreement, including form of Representatives Warrants (1)                                                                             
|       | 
|4.2    |  | Certificate of Designation, Preferences and Rights of Series A 7% Convertible Preferred Stock of NMHC (5)                                              
|       | 
|10.1   |  | Credit Agreement dated January 28, 2005 among NMHC, the Lenders party thereto and JPMorgan Chase, as Administrative Agent (7)                          
|       | 
|10.2   |  | Lease Expansion and Modification Agreement dated July 31, 2003 between Sunbeam Development Corporation and NMHCRx Mail Order, Inc. (3)                 
|       | 
|10.3   |  | AmerisourceBergen Prime Vendor Agreement, dated May 1, 2006 between NMHCRx Mail Order, Inc. d/b/a NMHCmail and AmerisourceBergen Drug Corporation (3) *
|       | 
|10.4   |  | Amendment to Lease Agreement, dated as of October 23, 2003, by and among BFS Realty, LLC and National Medical Health Card Systems, Inc. (4)            
|       | 
|10.5   |  | Form of Stock Option Agreement between NMHC and Non-Employee Directors (9)                                                                             
|       | 
|10.6   |  | Form of Stock Option Agreement between NMHC and Senior Executive Officers (9)                                                                          
|       | 
|10.7   |  | Form of Severance Agreement for Senior Executive Officers (9)                                                                                          
|       | 
|10.8   |  | Form of Excise Tax Gross-Up (10)                                                                                                                       
|       | 
|10.9   |  | Agreement between NMHC and Mr. Thomas W. Erickson, dated February 23, 2007 (11)                                                                        
|       | 
|10.10  |  | Form of Stock Option Agreement between NMHC and Mr. Thomas W. Erickson, dated March 12, 2007.                                                          
|       | 
|31.1   |  | Rule 13a-14(a)/15d-14(a) Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act                                                        
|       | 
|31.2   |  | Rule 13a-14(a)/15d-14(a) Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act                                                        
|       | 
|32.1   |  | Section 1350 Certification of CEO as adopted by Section 906 of the Sarbanes-Oxley Act                                                                  
|       | 
|32.2   |  | Section 1350 Certification of CFO as adopted by Section 906 of the Sarbanes-Oxley Act                                                                  

---

|* | Portions of this exhibit have been omitted pursuant to a request for confidential treatment.
|- | --------------------------------------------------------------------------------------------



36



---

##### Table of Contents

NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC. AND SUBSIDIARIES

(All in thousands, except share amounts)



|(1) | Denotes document filed as an Exhibit to NMHCs Registration Statement on Form S-1 (Registration Number: 333-72209) and incorporated herein by reference.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------

|(2) | Denotes document filed as an Exhibit to NMHCs Definitive Proxy Statement on Schedule 14-A filed on December 21, 2001 and incorporated herein by reference.
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------

|(3) | Denotes document filed as an Exhibit to NMHCs Report on Form 10-K for the year ended June 30, 2006 and incorporated herein by reference.
|--- | -----------------------------------------------------------------------------------------------------------------------------------------

|(4) | Denotes document filed as an Exhibit to NMHCs Report on Form 10-K/A Amendment Number 2 for the year ended June 30, 2003 and incorporated herein by reference.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------

|(5) | Denotes document filed as an Exhibit to NMHCs Form 10-Q for the quarter ended March 31, 2004 and incorporated herein by reference.
|--- | -----------------------------------------------------------------------------------------------------------------------------------

|(6) | Denotes document filed as an appendix to NMHCs Definitive Proxy Statement on Schedule 14-A filed on October 28, 2005 and incorporated herein by reference.
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------

|(7) | Denotes document filed as an exhibit to NMHCs Form 8-K filed on February 3, 2005 and incorporated herein by reference.
|--- | -----------------------------------------------------------------------------------------------------------------------

|(8) | Denotes documents filed as an Exhibit to NMHCs Form 10-Q for the quarter ended September 30, 2005 and incorporated herein by reference.
|--- | ----------------------------------------------------------------------------------------------------------------------------------------

|(9) | Denotes documents filed as an Exhibit to NMHCs Form 10-Q filed for the quarter ended December 31, 2005 and incorporated herein by reference.
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------

|(10) | Denotes document filed as an Exhibit to NMHCs Form 8-K filed on September 22, 2006 and incorporated herein by reference.
|---- | -------------------------------------------------------------------------------------------------------------------------

|(11) | Denotes document filed as an Exhibit to NMHCs Form 8-K filed on February 28, 2007 and incorporated herein by reference.
|---- | ------------------------------------------------------------------------------------------------------------------------



37



---

##### Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.



|                  |  |                                            |  |                                      
|----------------- |  | ------------------------------------------ |  | -------------------------------------
|                  |  | NATIONAL MEDICAL HEALTH CARD SYSTEMS, INC.
|                  |  | (Registrant)                              
|                  |  |                                           
|Date: May 9, 2007 |  | By:                                        |  | /s/ James F. Smith                   
|                  |  |                                            |  | James F. Smith                       
|                  |  |                                            |  | President and Chief Executive Officer
|                  |  |                                            |  | (Principal Executive Officer)        
|                  |  |                                           
|                  |  | By:                                        |  | /s/ Stuart Diamond                   
|                  |  |                                            |  | Stuart Diamond                       
|                  |  |                                            |  | Chief Financial Officer              
|                  |  |                                            |  | (Principal Financial Officer)        



38